Discover Oncology

Review

Current insights and future directions of Li‑Fraumeni syndrome

Mohammad‑Salar Hosseini1,2,3

Received: 20 August 2024 / Accepted: 7 October 2024

© The Author(s) 2024 

  OPEN

Abstract
Li-Fraumeni syndrome is a rare yet serious hereditary cancer predisposition syndrome, marked by a significant early-
life increased risk of developing cancer. Primarily caused by germline mutations in the TP53 tumor suppressor gene, 
Li-Fraumeni syndrome is associated with a wide range of malignancies. Clinical management of Li-Fraumeni syndrome 
could be challenging, especially the lifelong surveillance and follow-up of patients which requires a multidisciplinary 
approach. Emerging insights into the molecular and clinical basis of Li-Fraumeni syndrome, coupled with advances in 
genomic technologies and targeted therapies, offer promise in optimizing risk assessment, early detection, and treatment 
strategies tailored to the unique clinical and molecular profiles of affected individuals. This review discusses Li-Fraumeni 
syndrome in more depth, reviewing molecular, genomic, epidemiological, clinical, and therapeutic aspects of this disease.

Keywords  Adolescents and young adults cancer · AYA  · Cancer predisposition syndromes · Hereditary cancer · 
Li-Fraumeni · p53 · TP53

1   Background

Li-Fraumeni syndrome (LFS), also addressed as the “Sarcoma, Breast, Leukemia, and Adrenal Gland” (SBLA) syndrome, is 
a rare autosomal dominant cancer predisposition syndrome [1]. First described over fifty years ago, the initial suspicion 
was raised by Frederick P. Li and Joseph F. Fraumeni as an “increased familial susceptibility to cancer” was observed “not 
only by the large number of members affected but by a seeming excess of multiple primary neoplasms”, suggesting a 
potentially familial origin of the observed malignancies [2, 3]. The diagnosis of LFS is challenging due to its heterogene-
ous clinical presentation and diagnostic controversies [4, 5]. Moreover, the surveillance of LFS patients poses a further 
challenge to clinicians, as the individuals commonly face recurrent states of malignancies, either due to genetic pre-
disposition or complications of previous cancer treatments [6, 7]. This review aims to provide comprehensive basic and 
clinical insight into LSF, discussing this syndrome’s genomic, epidemiological, and clinical aspects.

 *  Mohammad-Salar Hosseini, hosseini.msalar@gmail.com; hosseinim@tbzmed.ac.ir | 1Research Center for Integrative Medicine in Aging, 
Aging Research Institute, Tabriz University of Medical Sciences, Golgasht Street, Tabriz 51666, EA, Iran. 2Hematology and Oncology 
Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 3Research Center for Evidence-Based Medicine, Iranian EBM Center: 
A JBI Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran.

 Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w

Vol.:(0123456789)Review 

Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w

2   Main text

2.1   Molecular and genomic basis

LFS is primarily associated with germline mutations in the TP53 gene, located on chromosome 17p13 [8, 9]. TP53 encodes 
the p53 protein, a critical tumor suppressor involved in regulating cell cycle progression, DNA repair, apoptosis, and 
senescence, with its alterations widely contribute to cancer development [10, 11]. The loss of the tumor suppressor func-
tion results in impaired cell cycle regulation, uncontrolled cell proliferation, increased genomic instability, and ultimately, 
predisposes the affected individuals to cancer development [12–14]. Therefore, TP53 holds fundamental regulatory roles 
in maintaining cellular responses to stressors, including DNA damage, hypoxia, and oxidative stress, thereby safeguarding 
genomic integrity [15, 16]. Figure 1 demonstrates the impact of TP53 mutation in terms of genomic and cellular pathways.
The spectrum of TP53 mutations linked to LFS includes various molecular abnormalities, including missense muta-
tions, frameshift mutations, in-frame mutations, splice site mutations, and nonsense mutations [17, 18]. As the most 
common mutations in this case, missense mutations result in the amino acid sequence alterations in the p53 protein, 
compromising its structural integrity and functional competence (Fig. 2). Nonsense mutations cause the p53 protein to 
prematurely truncate, eliminating its tumor suppressor properties and precipitating the onset of an aggressive neoplastic 
phenotype. Comparably, frameshift mutations disrupt the reading frame of TP53, resulting in aberrant protein translation 
and functional incapacitation, while splice site mutations interrupt the fidelity of RNA splicing, thereby engendering 
diverse phenotypic outcomes, depending on the resulting transcript variants [19, 20].

The nucleotide mutation patterns are dominantly C-to-T transitions at CpG dinucleotides, prone to methylation and 
subsequent deamination, making them hotspots for mutations [21]. Other substitutions, such as G-to-A or A-to-G tran-
sitions, occur less frequently and tend to have varying impacts on p53’s function [22]. Figures 2 and 3 exhibit the distri-
bution of TP53 mutation variants and mutation effects, highlighting the non-random nature of TP53 mutations, with a 
marked preference for specific types of transitions and transversions.

Although mutations have been detected in almost every codon, the majority of pathogenic TP53 mutations occur 
within exons 5 to 8 in the DNA-binding domain (around codons 100 to 300), which is crucial for the protein’s ability to 
mediate tumor suppression [21, 23, 24]. Mutations in the transactivation domain are less common but can disrupt the 

Fig. 1   The impact of TP53 mutation in cellular mechanisms and pathways

Vol:.(1234567890)Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w 

Review

Fig. 2   Distribution of TP53 
mutation effect (N = 28,866 – 
data from TP53 Database, R20)

Fig. 3   TP53 mutation variant distribution based on the mutation patterns (N = 28,866 – data from TP53 Database, R20)

pro-apoptotic abilities of p53 [25, 26]. Mutations can also occur in the oligomerization domain (exons 9 and 10), often 
impairing the structural integrity and stability [17, 27]. Codons 175, 245, 248, 273, and 282 are among the most com-
mon hotspot mutations [21, 23]. Additionally, specific founder variants of TP53 have also been observed in particular 
populations, such as R337H and P47S, which are more prevalent among Brazilians and individuals of African descent, 
respectively, both affecting non-DNA-binding domains [28, 29]. R337H mutation has contributed to a high incidence of 
adrenocortical carcinoma (ACC), but is notable for its incomplete penetrance [30]. Moreover, Some missense mutations 
in TP53 have a dominant-negative effect, meaning the mutant p53 protein not only loses its tumor-suppressive function 
but also interferes with the function of the remaining wild-type p53, exacerbating the cancer risk [31]. Hotspot mutations 
such as R175H, R248Q, and R273H are examples of dominant-negative mutations [32, 33].

Considering the higher prevalence of hotspot mutations, the profound impact of dominant-negative mutations, and 
the co-prevalence of founder variations with specific cancer types, recent studies and secondary analyses have focused 
on potential genotype–phenotype correlations [34, 35]. Although the hotspot variations show a likely shift toward 
early-onset (before 31) breast cancer and sarcoma, current evidence is inconclusive for any significant correlations [36]. 
There is still significant variability in how TP53 mutations manifest clinically. Even within families, individuals with the 
same TP53 mutation can present with different malignancies, different onset ages, and varying treatment responses [37].

2.2   Epidemiology

Studies have shown that LFS is a rare hereditary cancer predisposition syndrome with an estimated prevalence ranging 
from 1 in 5,000 to 1 in 20,000 individuals in the general population [38]. Geographically, LFS exhibits global distribution 

Vol.:(0123456789)Review 

Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w

without remarkable ethnic or racial preferences, although certain populations may exhibit founder mutations or higher 
prevalence rates attributable to genetic drift, population bottlenecks, or consanguinity [39, 40]. Despite its rarity, LFS 
exhibits considerable variability in penetrance and expressivity, with inter-individual variability in tumor spectrum, age 
of onset, and disease trajectory, attributable to modifier genes, environmental influences, and stochastic and random 
events [41–44].

The general viewpoint on LFS suggests a high penetrance of this familial syndrome, with about 80% risk of can-
cer during the individual’s lifespan [45, 46]. Studies estimate that over 350,000 individuals have germline TP53 muta-
tions—substantially more than registered cases—suggesting either a potential underdiagnosis of LFS cases worldwide 
or variation in its estimated penetrance [47, 48]. Also, there have been several reports of individuals with rare early-onset 
malignancies and TP53 mutations who have had a negative familial history of cancer, suggesting a potentially higher 
prevalence of LFS than estimated [49–52].

Tables 1 and 2 present the tumor site distribution of TP53 germline mutations in confirmed carriers and mutations 
identified in human tumor samples, retrieved from the R20 release of TP53 database [53, 54]. As presented, breasts, soft 
tissues, brain, adrenal glands, and bones are the most common tumor sites in individuals with TP53 germline mutations.
Around half of the TP53 mutation carriers are expected to develop cancer before the age of 30 [55, 56]. Notably, 
the prevalence of LFS may be underestimated due to challenges in clinical detection, diagnostic ascertainment, and 
genetic testing accessibility [57, 58]. The advent of next-generation sequencing (NGS) technologies and expanding 
indications for genetic testing in oncology practice have facilitated the identification of novel germline TP53 mutations 
and expanded the clinical spectrum of LFS-associated malignancies beyond the classic triad of sarcomas, breast cancer, 
and brain tumors [59, 60].

2.3   Clinical features

LFS is characterized by a diverse spectrum of malignancies affecting multiple organ systems. Common tumors associ-
ated with LFS include soft tissue sarcomas, breast cancer, brain tumors (such as glioblastoma and medulloblastoma), 
adrenocortical carcinoma, and leukemia, particularly, acute lymphoblastic leukemia (ALL) [61, 62]. The age of onset for 
cancer in LFS is typically younger compared to the sporadic cases, with many tumors diagnosed during childhood or 
early adulthood [20]. Additionally, individuals with LFS are at increased risk of developing multiple primary cancers over 
their lifetime, further complicating management and surveillance strategies [63].

Table 1   Tumor site 
distribution of TP53 germline 
mutations in confirmed 
carriers (Tumor distribution 
N = 2591—data from TP53 
Database, R20: July 2019)

Tumor site

Breast
Soft tissues
Brain
Adrenal gland
Bones
Hematological
Colorectum
Lung
Skin
Ovary
Stomach
Kidney
Prostate
Testis
Liver
Head and neck
Esophagus
Larynx
Bladder
Others

Count (%) n = 2591

815 (31.46%)
315 (12.16%)
289 (11.15%)
247 (9.53%)
241 (9.3%)
108 (4.17%)
73 (2.82%)
72 (2.78%)
60 (2.32%)
49 (1.89%)
30 (1.16%)
23 (0.89%)
12 (0.46%)
10 (0.39%)
8 (0.31%)
8 (0.31%)
3 (0.12%)
3 (0.12%)
2 (0.08%)
223 (8.61%)

Vol:.(1234567890)Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w 

Review

Table 2   Tumor site 
distribution of TP53 mutations 
identified in human tumor 
samples of primary tissues, 
body fluids, and cell-lines, 
based on mutated samples 
per samples analyzed (Tumor 
distribution N = 28,866 – data 
from TP53 Database, R20: July 
2019)

Tumor site

Colorectum
Respiratory system
Breast
Female genital organs
Head and neck
Esophagus
Brain
Hematological
Bladder
Liver
Skin
Stomach
Pancreas
Male genital organs
Soft tissues
Bones
Kidney
Other

Count (%) n = 28,866

3673 (12.72%)
3528 (12.22%)
2928 (10.14%)
2887 (10%)
2874 (9.96%)
1891 (6.55%)
1871 (6.48%)
1707 (5.91%)
1522 (5.27%)
1210 (4.19%)
1063 (3.68%)
985 (3.41%)
492 (1.7%)
434 (1.5%)
432 (1.5%)
294 (1.02%)
149 (0.52%)
926 (3.21%)

2.3.1   Sarcoma

Sarcomas are a hallmark presentation of LFS, constituting a significant proportion of malignancies encountered 
in affected individuals. Sarcomas contribute to one-fourth of all tumors in LFS patients, with the majority of cases 
exhibiting before 50 years old [64].

The mesenchymal tumors arise from connective tissues, including but not limited to bones, cartilage, muscle, adi-
pose tissue, and blood vessels, in different locations such as extremities, retroperitoneum, and head and neck regions, 
resulting in malignancies such as osteosarcoma [65], Ewing sarcoma [66], chondrosarcoma [67], rhabdomyosarcoma 
[68], leiomyosarcoma [69], liposarcoma [70], angiosarcoma [71], malignant peripheral nerve sheath tumors (MPNSTs) 
[72], and gastrointestinal stromal tumors (GISTs) [73]. Sarcomas generally vary in histologic subtypes, and could be 
accompanied by diverse clinical presentations and therapeutic responses.

LFS-related sarcomas usually develop in childhood or early adulthood, often preceding the diagnosis of other 
LFS-associated malignancies. The clinical presentations of sarcomas in LFS are characterized by their heterogeneity 
and tendency for metastasis and dissemination through the body [74]; therefore, any clinical suspicion is typically 
followed by comprehensive imaging studies and histopathological evaluations [75]. Rhabdomyosarcoma and osteo-
sarcoma are among the most common sarcoma subtypes encountered in LFS [8].

2.3.2   Breast cancer

In addition to sarcomas, LFS patients are at a significantly greater risk of breast cancer. In fact, breast cancer is the 
most prevalent cancer in female patients with LFS [76]. Previous studies have indicated that women with LFS experi-
ence breast cancer almost three decades earlier than the general population, usually with a mean onset age of around 
32–38 [76–79]. Studies have suggested the potential impact of reproductive factors since significant protective effects 
of breastfeeding for over seven months have been observed in respective populations [80].

Breast cancer in the context of LFS often exhibits aggressive histopathological features, including high histologic 
grade and overexpression of HER2/neu oncogene, tending towards an inferior overall survival compared to spo-
radic cases [77, 81]. Many LFS cases of breast cancer are estrogen receptor (ER) and human epidermal growth factor 
receptor 2 (HER2)-positive, suggesting the potential association of early-onset HER2-positive breast cancer with the 
presence of TP53 mutations [82].

Vol.:(0123456789)Review 

Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w

Clinical presentations of breast cancer are diverse and could be the earliest presenting signs and symptoms of LFS. 
Notably, breast cancers in LFS frequently emerge at a younger age compared to sporadic cases, making early breast 
cancer an alarming sign for clinicians to initiate an in-depth workup for LFS [56, 76, 83].

2.3.3   Brain tumors

Central nervous system (CNS) tumors could range from high-grade gliomas, namely glioblastoma multiforme, to embryo-
nal tumors, such as medulloblastoma, with variable histologic subtypes and clinical behaviors [84, 85]. These CNS tumors 
may present with neurological symptoms, including headaches, seizures, focal deficits, and merely cognitive impairments, 
prompting diagnostic evaluation with further neuroimaging modalities [86].

Glioma, including astrocytoma, oligodendroglioma, and glioblastoma, along with medulloblastoma and choroid 
plexus carcinoma, are the most common subtypes of brain cancer associated with LFS [85, 87–89]. Glioma exhibits infil-
trative growth patterns and aggressive histologic features, commonly with therapeutic resistance [90, 91]. Medulloblas-
toma is another LFS-associated brain tumor arising from the cerebellum, characterized by the propensity for metastatic 
dissemination via cerebrospinal fluid (CSF) [92].

2.3.4   Adrenocortical carcinoma

On the other hand, ACC could present with nonspecific or constitutional symptoms such as abdominal pain. Although 
ACC cases are generally sporadic, further evaluation for genetic predispositions such as LFS or multiple endocrine neo-
plasia (MEN) syndrome is recommended upon diagnosis [93].

Arising from the adrenal cortex, ACC usually presents with an aggressive clinical course, propensity for metastatic 
spread, and poor prognosis [94]. The clinical presentations of ACC in LFS are variable and nonspecific, often mimick-
ing symptoms of other adrenal disorders, including Cushing’s syndrome, or constitutional symptoms such as fatigue, 
weight loss, and abdominal fullness [95]. Notably, ACC may also be accidentally detected in imaging studies performed 
for unrelated indications, or during treatment for other diagnoses [96].

2.3.5   Hematologic malignancies

Hematologic malignancies might not be the initial denoting manifestation of LFS, but, in the case, they could present 
with unspecific or constitutional symptoms, along with splenomegaly, lymphadenopathy, or blood count abnormalities 
in further clinical evaluation and workup [97]. Although LFS accounts for less than 1% of ALL cases—the most frequently 
reported LFS-linked leukemia—in children, it comes with a significant predisposition to adverse treatment outcomes 
and second cancers [97, 98]. Furthermore, studies have reported an estimated six times higher risk of developing leu-
kemia in the LFS population [99]. Acute myeloid leukemia (AML), myelodysplastic syndromes, and lymphomas are also 
linked to LFS, but present with lower incidence [100]. TP53 mutation and LFS are linked to 10–15% and 5% of AML cases, 
respectively [101].

As a consequence of dysregulated proliferation and differentiation of hematopoietic precursors, culminating in the 
emergence of abnormal hematopoietic clones with malignant potential, hematologic malignancies often display aggres-
sive clinical behaviors in LFS patients, with resistance to conventional therapies, relapse, and propensity for recurrence 
[102–105].

2.3.6   Other presentations

Not all cases of LFS typically present with the discussed presentations, as many LFS cases have been reported with other 
malignancies. For instance, some studies have indicated melanoma as a potentially LFS-related malignancy; however, 
the association between LFS and melanoma is currently indefinite [106–108].

Figure 4 displays the most common tumor sites and clinical presentations of LFS.

Vol:.(1234567890)Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w 

Review

Fig. 4   The most common malignancies of Li-Fraumeni syndrome, along with their most common clinical presentations

2.4   Diagnosis

The diagnosis of LFS should be based on a combined clinical and genetic approach. Nonetheless, the definite diagnosis 
of LFS relies on TP53 mutation. However, several diagnostic criteria have been introduced to help clinicians effectively 
diagnose LFS and Li-Fraumeni-like syndrome (LFLS) cases, including the classic criteria, Chompret and its updated cri-
teria, the Birch criteria, and the Eeles criteria [110–113]. Table 3 summarizes the proposed criteria for both LFS and LFLS.

The classic criteria for LFS include:

1.  Diagnosis of sarcoma before age 45 in an individual
2.  A relative (first-degree) with any cancer before age 45
3.  Another relative (first-/second-degree) with any cancer before age 45, or a sarcoma at any age

Individuals meeting the clinical criteria are referred to genetic testing for TP53 mutations. In addition to genetic test-
ing, comprehensive familial pedigree analysis plays a vital role in clarifying the hereditary basis of cancer predisposition 
syndromes, including LFS. Patients with other combinations for personal or familial history of malignancies could still 
be considered clinically high-risk for LFS and managed accordingly. Importantly, in cases of high clinical suspicion, a 
negative result for the detectable pathogenic variants does not exclude the LFS diagnosis [114].

The National Comprehensive Cancer Network (NCCN) recommends testing for individuals complying with CRIT-7 
(testing criteria for LFS), including individuals fulfilling classic LFS or Chompret criteria, individuals with personal/famil-
ial history of pediatric hypodiploid ALL, and people with cancer with a pathogenic/likely pathogenic (P/LP) TP53 vari-
ant identified on tumor-only genomic testing, with germline evaluation considered in patients with an age of cancer 
diagnosis before 30 years old, or per clinician discretion [115]. However, in case the criteria are unmet, testing for other 
hereditary syndromes should be considered.

Vol.:(0123456789)Review 

Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w

Table 3   Diagnostic criteria for Li-Fraumeni syndrome, requiring further screening for germline TP53 mutation

Disease

Diagnostic criteria

Description

Li-Fraumeni syndrome

Classic criteria

Chompret criteria (updated)

Li-Fraumeni-like syndrome

Birch criteria

Eeles criteria

2.5   Management, surveillance, and screening

Presence of all the following:
- Sarcoma diagnosed at age < 45 years;
- First-degree relative < 45 with any cancer;
- First/second-degree relative with sarcoma at any age or any cancer < 45 years
The presence of one of the following:
- Tumor from the Li-Fraumeni spectrum (sarcoma, breast cancer, central nerv-
ous system tumor, adrenocortical carcinoma, leukemia, or lung cancer) < 46, 
and at least one first/second-degree relative with Li-Fraumeni tumor (except 
breast cancer if the proband has breast cancer) < 56 or with multiple tumors;
- Multiple tumors (except multiple breast tumors), two of which belong to the 

Li-Fraumeni spectrum, with the first one occurring < 46;

- Diagnosis of adrenocortical carcinoma, choroid plexus tumor, or rhabdomyo-
sarcoma of embryonal anaplastic subtype, irrespective of age and family 
history

- Breast cancer < 31
Presence of all the following:
- Any childhood cancer, or sarcoma, brain tumor, or adrenocortical carcinoma 

diagnosed < 45;

- First/second-degree relative with a Li-Fraumeni spectrum cancer (sarcoma, 
breast cancer, brain tumor, adrenocortical carcinoma, or leukemia) at any 
age;

- First/second-degree relative with any cancer < 60
Two first/second-degree relatives with Li-Fraumeni spectrum tumor at any age

Considering the high risk of developing cancer at a young age, individuals with LFS require lifelong surveillance and 
screening to detect tumors at an early, potentially curable stage. The preferred screening modalities and intervals 
should be based on the treating physicians’ discretion. Although there are controversies among current surveillance 
protocols, some routine screenings are recommended in most guidelines, including [109, 114, 116, 117]:

–  Triannual (until 18) or biannual/annual (after 18) clinical examination
–  Annual whole-body magnetic resonance imaging (MRI)
–  Bi/triannual abdominopelvic ultrasound
–  Annual breast MRI and mammography for women starting at age 20
–  Routine blood and urinary workup, including a complete blood count with differentials, along with blood inflam-

matory markers and available cancer biomarkers–a peripheral blood smear could also be helpful

–  Annual brain MRI
–  Colonoscopy every 2–5 years, beginning from age 18–25

Table 4 compares LFS surveillance protocols from the latest guidelines and consensuses in more detail [109, 
114–118]. Recent studies have also proposed novel cell-free DNA (cfDNA) approaches toward early cancer detection 
in LFS patients [119].

Routine clinical examination is necessary for LFS patients [120]. Starting from basic vital signs, clinicians should 
look after any indicating symptoms and signs, including pallor, unexplained weight loss, Cushing’s-like facial features, 
night sweet, persistent or progressive pain, sense of lump, bulge, or swelling, headache, seizure, visual disturbance in 
any form, hemoptysis, chest pain, shortness of breath, or any skin changes. The management of LFS requires a multi-
disciplinary approach, involving genetic counseling, cancer surveillance, risk reduction strategies, and personalized 
treatment interventions. Lifestyle modifications should be made to reduce cancer risk, including smoking cessation 
and maintaining a healthy weight [121].

Clinicians should consider that patients with TP53 mutations with a history of previous malignancy are prone to the 
development of a second cancer [122]. Radiation-induced malignancies are one of the more prevalent malignancies 

Vol:.(1234567890)Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w 

Review

i

-
l
e
p
o
n
m
o
d
b
A
-

o
t
h
t
r
i
b
m
o
r
F

i

-
n
m
o
d
b
A
-

o
t
h
t
r
i
b
m
o
r
F

l

i

a
n
m
o
d
b
A
-

o
t
h
t
r
i
b
m
o
r
F

i

-
n
m
o
d
b
A
-

h
t
r
i
b
m
o
r
F

m
4
-
3
q

,

S
U

-

n

i

i

g
n
n
n
g
e
B

i

m
4
-
3
q

,

S
U
c
i
v

f
i
(

s
t
s
e
t
d
o
o
B
-

l

-
i
s
s
o
p
m

i

S
U

c

m
4
-
3
q

,
)
e
b

l

-
t
a
s
n
u
S
U

f
i
(

q

,
)
y
r
o
t
c
a
f
s
i

m
6
-
3

b
s
t
s
e
 t
d
o
o
B
-

l

m
6
-
3

i

s
d
o
r
e
t
s
e
n
i
r
U

-

t
o
n
S
U

f
i
(

q

,
)
l
u
f
e
s
u

m
6

-
t
a
s
n
u
S
U

f
i
(

b
s
t
s
e
 t
d
o
o
B
-

l

m
4
-
3

,
)
y
r
o
t
c
a
f
s
i

m
4
–
3
q

y
7
1

q

,

S
U
c
i
v
e
p
o

l

y
8
1

m
6
q

,

S
U

y
8
1

q

,

S
U
c
i
v
e
p
o

l

)
y
8
1
o
t
(

y
c
n
a
f
n

i

f

y
 1
q

,
I

R
M
n
a
r
B
-

i

h
t
r
i
b
m
o
r
F

,
d
I
R
 M
n
a
r
B
-

i

h
t
r
i
b
m
o
r
F

I

R
M
n
a
r
B
-

i

o
t
h
t
r
i
b
m
o
r
F

,
I

R
M
n
a
r
B
-

i

h
t
r
i
b
m
o
r
F

y
1
q

,
I

R
M
n
a
r
B
-

i

n

i

i

g
n
n
n
g
e
B

i

y
1
q

3
5
P
T
k
s
i
r

,
e
s
t
n
a
i
r
a
 v

-
h
g
h
n

i

i

y
1
q

y
8
1

d
y
 1
q

y
c
n
a
f
n

i

i

-
l
e
p
o
n
m
o
d
b
A
-

m
4
-
3
q

,

S
U
c
i
v

q

,

a
s
t
s
e
 t
d
o
o
B
-

l

m
4
-
3

l

)
e
b
i
s
a
e
f

f
i
(

l

o
s

-
i
t
r
o
c
e
n
i
r
u
h
4
2
-

o
t
h
t
r
i
b
m
o
r
F

-
o
n
e
r
d
A

y
0
4

a
m
o
n
i
c
r
a
c

l

a
c
i
t
r
o
c

y
1
q

,
I

R
M
n
a
r
B
-

i

h
t
r
i
b
m
o
r
F

r
o
m
u
t
n
a
r
B

i

]
4
1
1
[

)
1
2
0
2
(

p
u
o
r
G
t
r
e
p
x
E
S
F
L
e
s
e
n
a
p
a
J

]
8
1
1
[

)
0
2
0
2
(

H
G
E
A
&
M
O
E
S

]
9
0
1
[

I

)
0
2
0
2
(
S
R
U
T
N
E
G

]
7
1
1
[

)
7
1
0
2
(
R
C
A
A

]
5
1
1
[

)
4
2
0
2
(

N
C
C
N

]
6
1
1
[

)
6
1
0
2
(

l

o
c
o
t
o
r
P
o
t
n
o
r
o
T

e
c
n
a

l
l
i

e
v
r
u
S

t
n
e
n
o
p
m
o
C

s
n
o
i
t
a
d
n
e
m
m
o
c
e
r
d
n
a
s
e
n

i
l

i

e
d
u
g
t
s
e
t
a

l

e
h
t
n
o
d
e
s
a
b
s
l
o
c
o
t
o
r
p
e
c
n
a

l
l
i

e
v
r
u
S

4
e
l
b
a
T

n
o
i
t
a
n
m
a
x
e

i

)
-
f
l
e
s
(

t
s
a
e
r
B
-

s
d
r
a
w
n
o

,

m
a
x
e
t
s
a
e
r
b

s
d
r
a
w
n
o

y
1
q

y
5
6

s
s
e
n

s
d
r
a
w
n
o

y
8
1
m
o
r
F

l

a
c
i
n

i
l

,
I

R
M
n
a
r
B
-

i

o
t
8
1
m
o
r
F

y
1
q

y
0
5

C
-

y
8
1
m
o
r
F

,
I

R
M

t
s
a
e
r
B
-

o
t
8
1
m
o
r
F

-
e
r
a
w
a
t
s
a
e
r
B
-

y
8
1
m
o
r
F

s
s
e
n
e
r
a
w
a
t
s
a
e
r
B
-

m
6
q

k
y
 1
q

,
I

R
M

t
s
a
e
r
B
-

y
5
7
o
t
0
2
m
o
r
F

t
s
a
e
r
b

)
l
a
c
i
n

i
l

C

(

-

,

n
o
i
t
a
n
m
a
x
e

i

s
d
r
a
w
n
o

y
1
q

y
5
7

y
0
2
m
o
r
F

,
I

R
M

t
s
a
e
r
B
-

o
t
0
2
m
o
r
F

m
6
q

m
6
q

,

n
o
i
t
a
n
m
a
x
e

i

t
s
a
e
r
b

l

a
c
i
n

i
l

C
-

s
d
r
a
w
n
o

y
0
2
m
o
r
F

,
I

R
M

t
s
a
e
r
B
-

o
t
0
2
m
o
r
F

k
y
 1
q

y
5
7

:

i

g
n
n
e
e
r
c
s

t
s
a
e
r
B
-

t
s
a
e
r
B

:
h
y
9
2
-
0
2
•

j

y
 1
q

,

i

I

R
 M

-
a
r
g
o
m
m
a
m
+

i

I

R
 M

t
s
a
e
r
B

:

y
5
7
-
0
3
•

q

,

n
o
i
t
a
n
m
a
x
e

i

t
s
a
e
r
b

l

a
c
i
n

i
l

C
-

m
2
1
-
6

t
s
a
e
r
b
r
o
f
d
e
t
a
e
r
t

o
h
w
d
n
a

,
r
e
c
n
a
c

s
t
n
a
i
r
a
v
P
L
/
P
3
5
P
T
•

e
s
a
c
r
e
P

:

y
5
7
>

•

y
1
q

,

y
h
p

n
o
i
s
i
c
e
d

a
d
a
h
t
o
n
e
v
a
h

-
s
a
m

l

a
r
e
t
a

l
i

b

t
s
a
e
r
B

:

y
m
o
t
c
e
t

-
o
m
m
a
m
+

I

R
M

y
1
q

,

m
a
r
g

s
d
r
a
w
n
o

h
y
0
 2
m
o
r
F

,

n
o
i
t
a
n
m
a
x
e

i

t
s
a
e
r
b

l

a
c
i
n

i
l

C
-

m
6
q

m
1
q

g
y
5
2
-
0
2
m
o
r
F

s
d
r
a
w
n
o

y
1
q

,
I

R
M

t
s
a
e
r
b
d
n
a

y
h
p
a
r
g
o
m
m
a
M

-

o
t

g
y
0
 2
m
o
r
F

y
5
7

s
d
r
a
w
n
o

y
8
1
m
o
r
F

,

n
o
i
t
a
n
m
a
x
e

i

-
f
l
e
s

t
s
a
e
r
B
-

s
d
r
a
w
n
o

y
8
1
m
o
r
F

r
e
c
n
a
c
t
s
a
e
r
B

-
s
a
m
g
n
i
c
u
d
e
r
-
k
s
i
r

r
e
d
i
s
n
o
C
-

y
m
o
t
c
e
t

y
m
o
t
c
e
t
s
a
m

l

a
r
e
t
a

l
i

b

g
n
i
c
u
d
e
r
-
k
s
i
r

r
e
d
i
s
n
o
C
-

-
t
a

l
i

b
g
n
i
c
u
d
e
r
-
k
s
i
r

r
e
d
i
s
n
o
C
-

,

y
m
o
t
c
e
t
s
a
m
g
n
i
c
u
d
e
r
-
k
s
i
r

s
s
u
c
s
i
D

-

l

a
r
e
t
a

l
i

b
g
n
i
c
u
d
e
r
-
k
s
i
r

r
e
d
i
s
n
o
C
-

y
m
o
t
c
e
t
s
a
m

l

a
r
e

d
n
a

l

a
i
c
o
s
o
h
c
y
s
p
g
n
i
s
s
e
r
d
d
a

y
m
o
t
c
e
t
s
a
m

a
m
o
c
r
a
s
d
e
c
u
d
n
i
-
n
o
i
t
a
d
a
r
e
c
u
d
e
r

i

d
e
r
r
e
f
e
r
p
s
i

y
m
o
t
c
e
t
s
a
m

,
r
e
c
n
a
c

i

o
t
n
o
i
t
a
d
a
r
/
y
m
o
t
c
e
p
m
u

l

r
e
v
o

t
s
a
e
r
b
h
t
i

i

w
d
e
s
o
n
g
a
d
s
t
n
e
i
t
a
p
r
o
F
-

s
t
c
e
p
s
a
e
f
i
l
-
f
o
-
y
t
i
l

a
u
q

k
s
i
r

Vol.:(0123456789) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review 

Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w

q

,

y
p
o
c
s
o
d
n
e

y
5
-
2

d
n
a
r
e
p
p
U

-

I

G
r
e
w
o

l

s
d
r
a
w
n
o

f
o
s
e
s
a
c
n
i
(

i

s
u
o
v
e
r
p

l

i

a
n
m
o
d
b
a

y
l
i

m
a
f

r
o
T
R

f
o
y
r
o
t
s
i
h

l

a
t
c
e
r
o
o
c

l

y
5
q

,
)
r
e
c
n
a
c

i

s
u
o
v
e
r
p
f
o

l

i

a
n
m
o
d
b
a

T
R
r
e
c
n
a
c

l

a

i
l
i

m
a
f

r
o

f
o
y
r
o
t
s
i
h

l

a
t
c
e
r
o
o
c

l

,

y
p
o
c
s
o
n
o
o
c

l

y
5
-
2
q

r
o
i
r
p
h
t
i

w
s
t
n
e
i
t
a
P
-

/
y
d
o
b
e
o
h
w

l

y
5
-
2
q

:

T
R

l

i

a
n
m
o
d
b
a

y
d
o
b
-
e
o
h
W

l

-

o
t
h
t
r
i
b
m
o
r
F

y
d
o
b
-
e
o
h
W

l

-

h
t
r
i
b
m
o
r
F

y
d
o
b
-
e
o
h
W

l

-

o
t
h
t
r
i
b
m
o
r
F

y
d
o
b
-
e
o
h
W

l

-

o
t
h
t
r
i
b
m
o
r
F

y
5
q

,
)
r
e
c
n
a
c

n
y
 1
q

I

R
M

y
7
1

t
u
o
h
t
i

w

I

R
M

m
u
n

i

i
l

o
d
a
g

y
1
q

,
t
n
e
m

-
e
c
n
a
h
n
e

t
u
o
h
t
i

w

(

I

R
M

m
u
n

i

i
l

o
d
a
g

-
e
c
n
a
h
n
e

r
o
f

)
t
n
e
m

k
s
i
r
-
h
g
h

i

e
s
t
n
a
i
r
a
 v

3
5
P
T

s
t
n
e
i
t
a
p
r
o

r
o
i
r
p
h
t
i

w

-
o
m
e
h
c

,

T
R
/
y
p
a
r
e
h
t

y
1
q

y
8
1

y
1

,

q

I

R
M

y
8
1

y
1

,

q

y
c
n
a
f
n

i

y
1
q

,
I

R
M

y
8
1

e
n
o
b
d
n
a

a
m
o
c
r
a
s

y
5
d
e
d
n
e
m
m
o
c
e
r

t
n
e
m
t
a
e
r
t

r
e
t
f
a

s
i

y
p
o
c
s
o
n
o
o
c

l

I

R
M
y
d
o
b
-
e
o
h
W

l

-

n

i

i

g
n
n
n
g
e
B

i

y
d
o
b
-
e
o
h
W

l

-

o
t
h
t
r
i
b
m
o
r
F

e
u
s
s
i
t

t
f
o
S

]
4
1
1
[

)
1
2
0
2
(

p
u
o
r
G
t
r
e
p
x
E
S
F
L
e
s
e
n
a
p
a
J

]
8
1
1
[

)
0
2
0
2
(

H
G
E
A
&
M
O
E
S

]
9
0
1
[

I

)
0
2
0
2
(
S
R
U
T
N
E
G

]
7
1
1
[

)
7
1
0
2
(
R
C
A
A

]
5
1
1
[

)
4
2
0
2
(

N
C
C
N

]
6
1
1
[

)
6
1
0
2
(

l

o
c
o
t
o
r
P
o
t
n
o
r
o
T

e
c
n
a

l
l
i

e
v
r
u
S

t
n
e
n
o
p
m
o
C

)
d
e
u
n
i
t
n
o
c
(

4
e
l
b
a
T

y
5
2
m
o
r
F

y
p
o
c
s
o
n
o
o
C
-

l

y
8
1
m
o
r
F

y
p
o
c
s
o
n
o
o
C
-

l

y
8
1
m
o
r
F

-
s
o
d
n
e
r
e
p
p
U

-

y
5
2
m
o
r
F

d
n
a
y
p
o
c
s
o
n
o
o
C
-

l

s
d
r
a
w
n
o

e
s
a
c
n

i

y
l
n
o
(

s
d
r
a
w
n
o

d
n
a
y
p
o
c

s
d
r
a
w
n
o

,

y
p
o
c
s
o
d
n
e
r
e
p
p
u

s
d
r
a
w
n
o

m
y
5
 2
m
o
r
F

,

y
p
o
c
s
o
n
o
o
C
-

l

y
2
q

s
d
r
a
w
n
o

r
e
c
n
a
c
l

a
n

l

y
5
 2
m
o
r
F

i

-
i
t
s
e
t
n
o
r
t
s
a
G

i

-
l
e
p
o
n
m
o
d
b
A
-

y
1
q

,

S
U
c
i
v

,

n
k
y
 1
q

,
I

R
M

y
d
o
b
-
e
o
h
W

l

-

s
d
r
a
w
n
o

y
8
1
m
o
r
F

y
1
q

l

l

a
c
i
g
o
o
t
a
m
r
e
D

-

,

n
o
i
t
a
n
m
a
x
e

i

s
d
r
a
w
n
o

y
8
1
m
o
r
F

–

–

–

–

t
n
u
o
c
d
o
o
b

l

c
i
n
e
g
o
m
e
k

y
1
q

,
)
s
g
u
r
d

-
u
e

l

r
o
i
r
p

(

–

l

e
t
e
p
m
o
C
-

h
t
r
i
b
m
o
r
F

–

–

–

y
d
o
b
-
e
o
h
W

l

-

y
8
1
m
o
r
F

y
d
o
b
-
e
o
h
W

l

-

y
1
q

,
I

R
M

s
d
r
a
w
n
o

,

S
U
c
i
v
e
p
o

l

k
y
 1

,

q

I

R
M

i

-
n
m
o
d
b
A
-

y
1
q

s
d
r
a
w
n
o

y
8
1
m
o
r
F

–

–

–

–

l

-
i
g
o
o
t
a
m
r
e
D

-

i

-
a
n
m
a
x
e

l

a
c

y
1
q

,

n
o
i
t

s
d
r
a
w
n
o

y
8
1
m
o
r
F

–

–

–

–

–

–

y
1
q

,

n
o
i
t
a
n
m
a
x
e

i

s
d
r
a
w
n
o

,

n
o
i
t
a
n
m
a
x
e

i

s
d
r
a
w
n
o

l

l

a
c
i
g
o
o
t
a
m
r
e
D

-

y
8
1
m
o
r
F

l

l

a
c
i
g
o
o
t
a
m
r
e
D

-

y
8
1
m
o
r
F

a
m
o
n
a
e
M

l

m
4
-
3
q

,

S
U
c
i
v

i

-
l
e
p
o
n
m
o
d
b
A
-

y
d
o
b
-
e
o
h
W

l

-

y
1
q

,
I

R
M

s
d
r
a
w
n
o

y
8
1
m
o
r
F

–

–

q

,
o
s
t
s
e
 t
d
o
o
B

l

h
t
r
i
b
m
o
r
F

m
4
-
3

y
1
q

l

e
t
e
p
m
o
C
-

o
t
h
t
r
i
b
m
o
r
F

-
i
s
y
h
p
e
o
h
W

l

-

o
t
h
t
r
i
b
m
o
r
F

l

a
c
i
n

i
l

C
-

o
t
h
t
r
i
b
m
o
r
F

l

e
t
e
p
m
o
C
-

o
t
h
t
r
i
b
m
o
r
F

e
v
i
s
n
e
h
e
r
p
m
o
C
-

n

i

i

g
n
n
n
g
e
B

i

q

,

n
o
i
t
a
n
m
a
x
e

i

n
o
i
t
a
r
e
p
o
o
C
-

m
4
-
3

i

g
n
d
n
e
t
t
a
h
t
i

w

n
a
i
c
i
s
y
h
p

y
7
1

i

-
a
n
m
a
x
e

l

a
c

m
6
-
4
q

,

n
o
i
t

y
8
1

n
o
i
t
a
n
m
a
x
e

i

c
fi
i
c
e
p
s
h
t
i

w

f
o
s
n
g
i
s
o
t

n
o
i
t
a
z
i
l
i
r
i
v

n
o
i
t
n
e
t
t
a

y
l
r
a
e
r
o

d
n
a
y
t
r
e
b
u
p

-
s
e
r
p
d
o
o
b

l

m
6
q

,

e
r
u
s

-
e
r
u
s
a
e
m

f
o
t
n
e
m

y
7
1

,

n
o
i
t
a
n
m
a
x
e

i

l

a
c
i
s
y
h
p

t
n
e
m

s
s
e
s
s
a

r
o
f
P
C
P
y
b

l

a
c
i
d
e
m
y
n
a

n
r
e
c
n
o
c

m
4
-
3
q

t
p
m
o
r
P
-

-
i

m
a
x
e
c
i
g
o
o
r
u
e
n

l

n
o
i
c
i
p
s
u
s

f
o
x
e
d
n

i

i

h
g
h
h
t
i

w
n
o
i
t
a
n

s
r
e
c
n
a
c
e
r
a
r

r
o
f

-
g

i
l

a
m
d
n
o
c
e
s
d
n
a

i

g
n
d
u
l
c
n

i

,

n
o
i
t

i

s
r
o
v
v
r
u
s

r
e
c
n
a
c

m
2
1
-
6
y
r
e
v
e

n

i

s
e
i
c
n
a
n

y
8
1

i

-
a
n
m
a
x
e

l

a
c
i
s
y
h
p

y
c
n
a
f
n

i

q

,

n
o
i
t
a
n
m
a
x
e

i

l

a
c
i
s
y
h
p

m
4
-
3

l

a
c
i
d
e
m
y
n
a
r
o
f

P
C
P
y
b
t
n
e
m

-
s
s
e
s
s
a
t
p
m
o
r
P
-

n
r
e
c
n
o
c

y
8
1

t
n
e
m

s
s
e
s
s
a

y
1
q

,

A
S
P
-

s
d
r
a
w
n
o

y
0
4
m
o
r
F

l

e
t
e
p
m
o
C
-

o
t
h
t
r
i
b
m
o
r
F

–

–

i

/
a
m
e
k
u
e
L

a
m
o
h
p
m
y
l

r
e
c
n
a
c

e
t
a
t
s
o
r
P

l

a
r
e
n
e
G

Vol:.(1234567890) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w 

Review

,

n
o
i
t
a
n
m
a
x
e

i

m
6
q

t
p
m
o
r
P
-

i

g
n
d
n
e
t
t
a
y
b

r
o
f
n
a
i
c
i
s
y
h
p

l

a
c
i
d
e
m
y
n
a

t
n
e
m

s
s
e
s
s
a

n
o
n
e
m
o
n
e
h
p

m
6
q

,

n
o
i
t

]
4
1
1
[

)
1
2
0
2
(

l

a
c
i
s
y
h
p

l

e
t
e
p
m
o
C
-

s
d
r
a
w
n
o

i

-
a
n
m
a
x
e

l

a
c

y
8
1
m
o
r
F

-
i
s
y
h
p
e
o
h
W

l

-

s
d
r
a
w
n
o

y
8
1
m
o
r
F

n
o
i
t
a
n
m
a
x
e

i

c
fi
i
c
e
p
s
h
t
i

w

e
c
n
e
r
r
u
c
c
o

l
l

e
c
l

a
s
a
b
f
o

s
a
m
o
n
i
c
r
a
c

e
h
t
n
h
t
i

i

w

n
o
i
t
n
e
t
t
a

e
h
t
o
t

y
p
a
r
e
h
t
o
d
a
r

i

n

i

l

d
e
fi

o
h
w
s
t
n
e
i
t
a
p

l

a
c
i
n

i
l

C
-

,

n
o
i
t
a
n
m
a
x
e

i

m
6
q

t
p
m
o
r
P
-

t
n
e
m

s
s
e
s
s
a

r
o
f
P
C
P
y
b

l

a
c
i
d
e
m
y
n
a

n
r
e
c
n
o
c

s
d
r
a
w
n
o

y
8
1
m
o
r
F

l

a
c
i
s
y
h
p

l

e
t
e
p
m
o
C
-

s
d
r
a
w
n
o

y
8
1
m
o
r
F

,

T
R
d
e
v
e
c
e
r

i

y
1
q

i

e
n
o
d
e
n
e
t
s
o
r
d
n
a
d
n
a

i

n
o
i
t
a
n
m
a
x
e
c
i
g
o

l

f
o
x
e
d
n

i

i

h
g
h
h
t
i

w

e
r
a
r

r
o
f
n
o
i
c
i
p
s
u
s

-
c
e
s
d
n
a
s
r
e
c
n
a
c

s
e
i
c
n
a
n
g

i
l

a
m
d
n
o

-
o
r
u
e
n
g
n
d
u
l
c
n

i

i

m
a
x
e

l

a
c
i
s
y
h
p

,
s
r
o
v
v
r
u
s

i

r
e
c
n
a
c
n

i

m
2
1
-
6
q

e
v
i
s
n
e
h
e
r
p
m
o
C
-

d
o
o
h
t
l
u
d
A

l

a
n
o
s
r
e
p
t
n
u
o
c
c
a
o
t
n

i

e
k
a
t
d
u
o
h
s

l

y
0
1
-
5
(

r
e
c
n
a
c
f
o
y
r
o
t
s
i
h
y
l
i

m
a
f
d
n
a

)
s
i
s
o
n
g
a
d
t
s
e

i

i
l
r
a
e
e
r
o
f
e
b

s
n
o
i
t
a
d
n
e
m
m
o
c
e
r
g
n
n
e
e
r
c
S
-

i

q

,

n
o
i
t
a
n
m
a
x
e

i

m
4
-
3

l

a
c
i
d
e
m
y
n
a
r
o
f

P
C
P
y
b
t
n
e
m

-
s
s
e
s
s
a
t
p
m
o
r
P
-

n
r
e
c
n
o
c

l

a
c
i
s
y
h
p

l

e
t
e
p
m
o
C
-

s
d
r
a
w
n
o

y
8
1
m
o
r
F

p
u
o
r
G
t
r
e
p
x
E
S
F
L
e
s
e
n
a
p
a
J

]
8
1
1
[

)
0
2
0
2
(

H
G
E
A
&
M
O
E
S

]
9
0
1
[

I

)
0
2
0
2
(
S
R
U
T
N
E
G

]
7
1
1
[

)
7
1
0
2
(
R
C
A
A

]
5
1
1
[

)
4
2
0
2
(

N
C
C
N

]
6
1
1
[

)
6
1
0
2
(

l

o
c
o
t
o
r
P
o
t
n
o
r
o
T

,

e
t
a
f
l
u
s
e
n
o
r
e
t
s
o
r
d
n
a
p
e
o
r
d
y
h
e
d

i

,

e
n
o
r
e
t
s
o
t
s
e
t

l

a
t
o
t

,

e
n
o
r
e
t
s
e
g
o
r
p
-
H
O
-
7
1
e
d
u
l
c
n

i

i

e
n
o
d
e
n
e
t
s
o
r
d
n
a
d
n
a

,

e
t
a
f
l
u
s
e
n
o
r
e
t
s
o
r
d
n
a
p
e
o
r
d
y
h
e
d

i

i

e
n
o
d
e
n
e
t
s
o
r
d
n
a

,

e
n
o
r
e
t
s
o
r
d
n
a
p
e
o
r
d
y
h
e
d

i

,

e
n
o
r
e
t
s
o
t
s
e
t

l

a
t
o
t
e
d
u
l
c
n

i

,

e
n
o
r
e
t
s
o
t
s
e
t

l

a
t
o
t
e
d
u
l
c
n

i

)
d
e
u
n
i
t
n
o
c
(

4
e
l
b
a
T

e
c
n
a

l
l
i

e
v
r
u
S

t
n
e
n
o
p
m
o
C

s
t
s
e
t
d
o
o
 B
a

l

s
t
s
e
t
d
o
o
 B
b

l

s
t
s
e
t
d
o
o
 B
c

l

-
t
n
a
n
m
o
d

i

a

o
t

i

g
n
d
n
o
p
s
e
r
r
o
c

s
t
n
a
i
r
a
v

d
n
a

,
s
r
e
c
n
a
c

d
o
o
h
d

l
i

h
c

h
t
i

w
d
e
t
a
i
c
o
s
s
a

n
e
e
b

y
d
a
e
r
l
a

s
a
h

t
a
h
t

t
n
a
i
r
a
v

,
s
r
e
b
m
e
m
y
l
i

m
a
f
/
l
a
u
d
v
d
n

i

i

i

n

i

r
e
c
n
a
c

d
o
o
h
d

l
i

h
C

:
s
t
n
a
i
r
a
v

3
5
P
T

k
s
i
r
-
h
g
 H
e

i

t
n
a
i
r
a
v
e
s
n
e
s
s
i

m
e
v
i
t
a
g
e
n

y
t
i
l

a
m
r
o
n
b
a
w
e
n
o
n
d
n
a

l

a
m
r
o
n

I

R
M

i

s
u
o
v
e
r
p
f
i

t
s
a
r
t
n
o
c
t
u
o
h
t
i

w

r
e
t
f
a
e
r
e
h
t

,
t
s
a
r
t
n
o
c
h
t
i

w

I

R
M

t
s
r
i
 F
d

d
e
m
r
fi
n
o
c
e
r
a
s
e
i
t
i
l

a
m
r
o
n
b
a
w
e
n
o
n
d
n
a

l

a
m
r
o
n
s
i

I

R
M

i

s
u
o
v
e
r
p
e
h
t

s
a
g
n
o

l

s
a
y
r
a
s
s
e
c
e
n
t
o
n
s
i

t
s
a
r
t
n
o
c
r
e
t
f
a
e
r
e
h
t

,
t
s
a
r
t
n
o
c
h
t
i

w

I

R
M

t
s
r
i
 F

f

)
t
s
r
fi
s
e
m
o
c
r
e
v
e
h
c
i
h
w

(
y
l
i

m
a
f
e
h
t
n

i

n
o
i
t
c
e
t
e
d
r
e
c
n
a
c
t
s
a
e
r
b
t
s
e

i
l
r
a
e
e
h
t
e
r
o
f
e
b
s
r
a
e
y
n
e
t
o
t
e
v
fi
r

 O
g

y
0
2
<

f
i

,

y
l
i

m
a
f
e
h
t
n

i

r
e
c
n
a
c
t
s
a
e
r
b
d
e
s
o
n
g
a
d
t
s
e

i

i
l
r
a
e
e
h
t

f
o
e
g
a
e
h
t

t
a
r

 O
h

-
a
r
t
l
U
S
U

,

y
p
a
r
e
h
t
n
o
i
t
a
d
a
R
T
R

i

,

y
r
e
v
E
q

,

n
e
g
i
t
n
a
c
fi
i
c
e
p
s
-
e
t
a
t
s
o
r
P
A
S
P

,

n
a
i
c
i
s
y
h
p
e
r
a
c
y
r
a
m

i
r
P
P
C
P

,

c
i
n
e
g
o
h
t
a
p
y
l
e
k
i
l
/
c
i
n
e
g
o
h
t
a
P
P
L
/
P

,

i

g
n
g
a
m

i

e
c
n
a
n
o
s
e
r
c
i
t
e
n
g
a
M

I

R
M

,
)
s
(
h
t
n
o
M
m

,
r
u
o
H
h

k
r
o
w
t
e
N
e
c
n
e
r
e
f
e
R
n
a
e
p
o
r
u
E
S
I
R
U
T
N
E
G

-

N
R
E

,

h
c
r
a
e
s
e
R
r
e
c
n
a
C
r
o
f
n
o
i
t
a
i
c
o
s
s
A
n
a
c
i
r
e
m
A
R
C
A
A

,

k
r
o
w
t
e
N

r
e
c
n
a
C
e
v
i
s
n
e
h
e
r
p
m
o
C

l

a
n
o
i
t
a
N
N
C
C
N

,

e
m
o
r
d
n
y
s

i

n
e
m
u
a
r
F
-
i
L
S
F
L

,
)
s
(
r
a
e
Y
y

,

d
n
u
o
s

l

a
n
a
m
u
H
a
c
i
t
é
n
e
G
e
d
a
o
ñ
a
p
s
E
n
ó
i
c
a
i
c
o
s
A
H
G
E
A

,

í

l

l

a
c
i
d
é
M
a
g
o
o
c
n
O
e
d
a
o
ñ
a
p
s
E
d
a
d
e
i
c
o
S
M
O
E
S

,
s
e
m
o
r
d
n
y
S
k
s
i
R
r
o
m
u
T
c
i
t
e
n
e
G
e
h
t
n
o

)
s
r
e
i
r
r
a
c
t
n
a
i
r
a
v
P
L
/
P
n

i

e
r
u
s
o
p
x
e
n
o
i
t
a
d
a
r

i

f
o
k
s
i
r
e
h
t
g
n
d
r
a
g
e
r

i

s
n
r
e
c
n
o
c
o
t
e
u
d
d
e
r
r
e
f
e
r
p
s
i

I

R
M

t
s
a
e
r
B
(
e
b
a

l

l
i

a
v
a
n
u
s
i

I

R
M

f
i

,

m
a
r
g
o
m
m
a
m

r

 O

j

)

m
6
q
n
a
c
s
e
n
o
t
s
a
e

l

t
a
(

I

R
M
y
d
o
b
-
e
o
h
w

l

l

a
u
n
n
a
h
t
i

w
e
t
a
n
r
e
t
l
a
o
t
S
U
c
i
v
e
p
o
n
m
o
d
b
a
d
n
a

l

i

I

R
M

t
s
a
e
r
 B
k

)
t
s
r
fi
s
e
m
o
c
r
e
v
e
h
c
i
h
w

(
y
l
i

m
a
f
e
h
t
n

i

n
o
i
t
c
e
t
e
d
r
e
c
n
a
c
n
o
o
c
t
s
e

l

i
l
r
a
e
e
h
t
e
r
o
f
e
b
s
r
a
e
y
n
e
t

y
l
i

m
a
f
e
h
t
n

i

r
e
c
n
a
c
c
i
r
t
s
a
g
r
o

l

l

a
t
c
e
r
o
o
c
n
w
o
n
k
t
s
e

i
l
r
a
e
e
h
t
e
r
o
f
e
b
s
r
a
e
y
e
v
fi
r

r

 O

l

 O
m

s
b
m

i
l

l
l

i

a
g
n
d
u
l
c
n

i

,

e
o
t
o
t
d
a
e
h
m
o
r
f
d
e
m
r
o
f
r
e
p
s
i

I

R
M
y
d
o
b
-
e
o
h
 W

l

n

e
s
a
n
e
g
o
r
d
y
h
e
d
e
t
a
t
c
a

l

d
n
a

,

i

e
t
a
r
n
o
i
t
a
t
n
e
m
d
e
s
e
t
y
c
o
r
h
t
y
r
e

l

,
t
n
u
o
c
d
o
o
b
e
t
e
p
m
o
c
e
d
u
l
c
n

l

i

s
t
s
e
t
d
o
o
 B
o

l

t
s
a
r
t
n
o
c
t
u
o
h
t
i

w
d
n
a
h
t
i

 W

i

Vol.:(0123456789) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review 

Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w

among LFS patients with a history of previous malignancy [6, 123]. Given the significance of breast cancer in female 
patients with LFS, a total bilateral prophylactic mastectomy has also been recommended; however, this decision 
should be made according to each individual’s status of health and personal history of cancer, familial history, prin-
ciples, and wishes [124].

2.6   Treatment

There is no approved and definite treatment for LFS, and most LFS patients undergo the conventional treatment strate-
gies available for each cancer [114]. The management of LFS almost entirely depends on a combination of surveillance 
protocols, risk reduction strategies, and therapeutic interventions tailored to the specific tumor types and clinical char-
acteristics of affected individuals. The standard treatment regimens for LFS-related cancers have traditionally involved 
DNA-damaging systemic cytotoxic chemoradiation, which can lead to subsequent tumors [125]. Meanwhile, recent 
studies have explored alternative therapeutic strategies that may offer more targeted and less genotoxic options for 
LFS patients. Table 5 presents recent and ongoing clinical trials focusing on LFS patients. The most common proposed 
therapeutic candidates are:

2.6.1   Immune checkpoint inhibitors

Immune checkpoint inhibitors, chiefly the programmed cell death protein-1 and its ligand (PD-1/PD-L1)- and cytotoxic 
T-lymphocyte-associated protein-4 (CTLA-4)-targeting antibodies, have shown promising clinical activity in various solid 
tumors and hematologic malignancies associated with LFS [126, 127]. By blocking inhibitory signaling pathways in the 
tumor microenvironment, these agents could enhance the antitumor immune response, potentially leading to tumor 
regression and prolonged patient survival [128]. Studies evaluating immune checkpoint inhibitors as monotherapy or 
in combination with other therapeutic modalities are underway to assess their efficacy and safety in individuals with 
LFS-associated cancers, including the United States Food and Drug Administration (FDA)-approved Nivolumab and 
Pembrolizumab, and FDA-approval pending Sintilimab – which has been recently approved and included in the National 
Reimbursement Drug List (NRDL) of China (Table 5) [129–135].

2.6.2   Adoptive cell therapy

Adoptive cell therapy, including chimeric antigen receptor (CAR) T-cell therapy and tumor-infiltrating lymphocyte (TIL) 
therapy, is another proposed approach for the treatment of LFS-associated malignancies [136, 137]. CAR T-cell therapy 
involves engineering the patients’ T cells to express chimeric antigen receptors targeting specific tumor antigens, while 
TIL therapy involves isolating and expanding tumor-infiltrating lymphocytes with antitumor activity ex vivo before rein-
fusion into patients [138]. The CAR T-cell-based combination strategies have demonstrated improved overall survival in 
previous studies [139, 140].

2.6.3   Cytokine‑based therapies

Cytokine-based therapies, such as interleukin-2 (IL-2) and interferon-alpha (IFN-α), modulate the immune response and 
enhance the antitumor activity of immune effector cells, including T cells and natural killer (NK) cells [141, 142]. Cytokine-
based therapies have been investigated as either monotherapy or in combination with other immunotherapeutic agents 
for LFS-associated malignancies [143–145].

2.6.4   TP53 reactivators

Small molecule drugs designed to reactivate mutant TP53 proteins represent a promising therapeutic strategy for indi-
viduals with LFS-associated tumors [146, 147]. Eprenetapopt (PRIMA-1Met, APR-246) and RITA (Reactivating p53 and 
Inducing Tumor Apoptosis) have shown preclinical efficacy in restoring the transcriptional activity, inducing cell cycle 
arrest, and promoting apoptosis in cancer cells with dysfunctional TP53 [133, 148–150].

Vol:.(1234567890)Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w 

Review

-
r
i
c
n
o
n
o
i
t
a
r
t
s
i
n
m
d
a
n
m
r
o
f
t
e
m

i

i

y
b
t
n
e
m

s
s
e
s
s
a
y
t
i
c
i
x
o
t
(

s
r
a
e
y
2

f
o
t
c
e
ff
e
e
h
t

s
u
p

l

.

,
)
0
4
v
E
A
C
T
C

e
n

i
l

m
r
e
g
e
v
i
t
i
s
o
p
d
e
t
n
e
m

n
o
i
t
a
t
u
m
3
5
P
T

l

l

e
s
a
e
e
r
e
t
e
p
m
o
c
r
e
t
f
a

-
t
i
c
e
D
d
n
a

e
n
b
a

i

S
D
M

-
d

l
i

w
3
5
P
T

,

d
e
fi

i
l

p
m
a
2
M
D
M

c
i
t
a
e
r
c
n
a
p
/
t
c
a
r
t
y
r
a

i
l
i

b
e
p
y
t

d
n
a

,

a
m
o
n
i
c
r
a
c
o
n
e
d
a

l

a
t
c
u
d

s
r
o
m
u
t
d

i
l

o
s

r
e
h
t
o

-
P
1
3
e
h
t
g
n
i
s
u

,

n
o
i
t
a
t
n
e
m
e
p
p
u
s

l

l

a
m
i
x
a
m
b
u
s
e
l
c
s
u
m

l

l

a
t
e
e
k
s
S
R
M

f
o
s
k
e
e
w
2
1
o
t
e
n

i
l

e
s
a
b
m
o
r
f

e
s
i
c
r
e
x
e

n
o
i
t
a
t
u
m
3
5
P
T

3
P
B
F
G

I

d
n
a

,

n

i
l

u
s
n

i

,

1
-
F
G

I

g
n
i
t
a
u
c

l

)
s
r
a
e
y
o
w

t

:

e
m
a
r
f
e
m

i
t
(

t
n
e
m
e
r
u
s
a
e
m

,
t
n
a
t
s
n
o
c
e
m

i
t
y
r
e

e
d
i
s
o
b
i
r

d
e
m
r
fi
n
o
c
d
n
a
e
m
o
r
d
n
y
s

-
v
o
c
e
r
e
n
i
t
a
e
r
c
o
h
p
s
o
h
p
n

i

e
g
n
a
h
C

i

e
d
m
a
n
i
t
o
c
i
N

i

n
e
m
u
a
r
F
-
i
L
h
t
i

w

)
8
1
>

(

s
t
l
u
d
A

l

a
i
r
t

I
I
/
I

e
s
a
h
P

A
S
U

l

d
e
t
e
p
m
o
C

5
7
1
9
8
7
3
0
T
C
N

)
8
2
8
7
0
9

I

B
(

,

c
i
t
a
t
s
a
t
e
m
/
d
e
c
n
a
v
d
a
y
l
l

a
c
o

l

r
e
t
n
e
c

s
h
t
n
o
m
0
3
o
t
p
u

,
s
t
n
e
i
t
a
p
n

i

R
R
O

n

i
l

d
a
m
g
i
r
B

i

h
t
i

w
s
t
n
e
i
t
a
p

)
8
1
>

(

t
l
u
d
A

l

a
i
r
t

I
I

e
s
a
h
P

-
i
t
l
u
m

l

a
n
o
i
t
a
n
r
e
t
n

I

g
n
i
t
i
u
r
c
e
r

,

e
v
i
t
c
A

7
7
3
2
1
5
5
0
T
C
N

i

-
a
n
b
m
o
c
e
h
t

r
e
t
f
a
s
k
e
e
w

r
u
o
f
R
R
O

e
d
i
x
o
i
r
t
c
i
n
e
s
r
A

g
n
u
o
y
d
n
a
n
e
r
d

l
i

h
c
8
1
-
r
e
d
n
U

l

a
i
r
t

I
I

e
s
a
h
P

i

a
n
h
C

g
n
i
t
i
u
r
c
e
r

,

e
v
i
t
c
A

0
3
0
8
8
0
6
0
T
C
N

n
o
i
t
a
n
b
m
o
C

i

y
p
a
r
e
h
t
n
o
i
t

i

d
e
n
b
m
o
c

l

l

a
c
i
g
o
o
h
t
a
p
h
t
i

w
s
t
l
u
d
a

y
p
a
r
e
h
t

-
o
m
e
h
c
h
t
i

w

t
n
a
n
g

i
l

a
m

f
o
s
i
s
a
b
s
i
s
o
n
g
a
d

i

y
p
a
r
e
h
t

*
s
n
o
i
t
a
t
u
m
3
5
P
c
i
t
a
m
o
s

r
o
e
n

i
l

m
r
e
g
d
n
a
r
o
m
u
t

s
h
t
n
o
m
8
–
6
o
t
p
u

,
s
t
n
e
i
t
a
p
n

i

S
F
R

e
d
i
x
o
i
r
t
c
i
n
e
s
r
A

h
t
i

w

)
8
1
>

(

s
t
n
e
i
t
a
p
t
l
u
d
A

l

a
i
r
t

I
I
I

e
s
a
h
P

i

a
n
h
C

n
w
a
r
d
h
t
i

W

5
2
7
7
7
3
3
0
T
C
N

l

l

e
s
a
e
e
r
e
t
e
p
m
o
c
r
e
t
f
a

-
t
i
c
e
D

,

e
d

i

s
n
o
i
t
a
t
u
m
3
5
p
h
t
i

w

s
h
t
n
o
m
8
–
6
o
t
p
u

,
s
t
n
e
i
t
a
p
n

i

S
F
R

-
x
o
i
r
t
c
i
n
e
s
r
A

s
t
n
e
i
t
a
p
L
M
A

)
8
1
>

(

s
t
l
u
d
A

l

a
i
r
t

I
I

e
s
a
h
P

i

a
n
h
C

s
u
t
a
t
s
n
w
o
n
k
n
U

1
8
7
1
8
3
3
0
T
C
N

d
n
a

,

e
n
b
a

i

y
p
a
r
e
h
t
n
o
i
t

i

-
a
n
b
m
o
c
n

i

-
r
e
h
t
o
m
e
h
c

h
t
i

w
n
o
i
t

y
p
a

h
t
i

w
s
t
n
e
i
t
a
p
d
e
t
a
t
u
m
-
3
5
p

f
o
s
i
s
o
n
g
a
d

i

l

l

a
c
i
g
o
o
h
t
a
p

*
r
o
m
u
t

t
n
a
n
g

i
l

a
m

i

e
n
b
a
r
a
t
y
C

i

-
a
n
b
m
o
c
e
h
t

r
e
t
f
a
s
k
e
e
w

r
u
o
f
R
R
O

e
d
i
x
o
i
r
t
c
i
n
e
s
r
A

)
8
1
<

(

t
l
u
d
a
g
n
u
o
y
d
n
a
d

l
i

h
C

l

a
i
r
t

I
I

e
s
a
h
P

i

a
n
h
C

g
n
i
t
i
u
r
c
e
r

,

e
v
i
t
c
A

0
3
0
8
8
0
6
0
T
C
N

)
s
h
t
n
o
m
7
2
o
t
p
u
(
y
d
u
t
s

x
a
l
c
o
t
e
n
e
V
r
o

-
i
t
i
c
a
z
A
h
t
i

w

b
a
m

i
l

o
r
g
a
M

e
n
d

i

3
5
P
T
h
t
i

w

)
8
1
>

(

s
t
n
e
i
t
a
p

L
M
A
t
n
a
t
u
m

r
e
t
n
e
c

s
e
l
c
y
c
r
u
o
f

r
e
t
f
a

-
t
i
c
e
D
d
n
a

3
5
p
h
t
i

w
s
t
n
e
i
t
a
p
S
D
M
/
L
M
A

e
n
b
a

i

*
s
t
n
a
t
u
m

R
R
O
d
n
a

l

a
i
r
t
e
h
t
g
n
i
r
u
d
s
t
c
e
ff
e
e
d
S

i

e
d
i
x
o
i
r
t
c
i
n
e
s
r
A

)
8
1
>

(

t
l
u
d
a
d
e
s
o
n
g
a
d
y
l
w
e
N

i

l

a
i
r
t

I

e
s
a
h
P

i

a
n
h
C

g
n
i
t
i
u
r
c
e
r

,

e
v
i
t
c
A

1
7
3
5
5
8
3
0
T
C
N

f
o
d
n
e
r
o
h
t
a
e
d
o
t
p
u

,
s
t
n
e
i
t
a
p
n

i

S
O

f
o
n
o
i
t
a
n
b
m
o
C

i

ï

t
l
u
d
a
e
v
a
n
-
t
n
e
m
t
a
e
r
T

l

a
i
r
t

I
I
I

e
s
a
h
P

-
i
t
l
u
m

l

a
n
o
i
t
a
n
r
e
t
n

I

d
e
t
a
n
m
r
e
T

i

7
9
3
8
7
7
4
0
T
C
N

o
t
p
u

,

i

n
m
r
o
f
t
e
m

f
o
y
t
i
l
i

b
a
r
e
o
T

l

i

n
m
r
o
f
t
e
M

-
u
c
o
d
h
t
i

w

)
8
1
>

(

s
t
l
u
d
A

l

a
i
r
t

I

e
s
a
h
P

A
S
U

l

d
e
t
e
p
m
o
C

5
2
5
1
8
9
1
0
T
C
N

y
p
a
r
e
h
t
o
n
o
M

s
e
m
o
c
t
u
o
y
r
a
m

i
r
p
d
e
r
u
s
a
e
M

)
s
(
n
o
i
t
n
e
v
r
e
t
n

I

l

n
o
i
t
a
u
p
o
p
y
d
u
t
S

e
p
y
t
y
d
u
t
S

y
r
t
n
u
o
C

s
u
t
a
t
s
y
d
u
t
S

D

I

v
o
g
.
s
l
a
i
r
t
l
a
c
i
n

i
l

C

p
u
o
r
g

l

a
i
r
T

n
o
i
t
a
t
u
m
3
5
P
T
d
n
a
e
m
o
r
d
n
y
s

i

n
e
m
u
a
r
F
-
i
L
d
e
t
n
e
m
u
c
o
d
r
o
f

s
l
a
i
r
t
d
e
r
e
t
s
i
g
e
r
g
n
o
g
n
o
d
n
a
t
n
e
c
e
R

i

5
e
l
b
a
T

Vol.:(0123456789) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review 

Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w

d
n
a
b
a
m
u
z

x
a
l
c
o
t
e
n
e
V

-
u
t
u
n
b
O

i

-
d
r
o
c
c
a
t
n
e
m
t
a
e
r
t
g
n
i
r
i
u
q
e
r

e
h
t

f
o
e
n
o
t
s
a
e

l

t
a
o
t
g
n

i

L
L
S
/
L
L
C
d
e
t
n
e
m
u
c
o
d

,
)
R
B
E
(
y
p
a
r
e
h
t

-
e
s
o
d
-
h
g
h

i

l

i

a
n
g
a
v
e
t
a
r

-
y
h
c
a
r
b

d
n
a

,

y
p
a
r
e
h
t

b
i
r
a
p
a
r
i

N

l

a
i
r
t
e
m
o
d
n
e
s
u
o
r
e
s
e
r
u
p

-
o
t
s
i
h
r
e
h
t
o
r
o
a
m
o
n
i
c
r
a
c

i

d
n
a
d
o
i
r
t
e
m
o
d
n
e
(

s
e
p
y
t

/
l
a
m
r
o
n
b
a
h
t
i

w

)
l
l

e
c
r
a
e
l
c

3
5
p
e
p
y
t
-
t
n
a
t
u
m

s
r
a
e
y
2

b

i
l
c
i
c
a
m
e
b
A

-
i
l

o
r
b
m
e
P
s
v

b
a
m
u
z

-
o
d
n
e
e
p
y
t
-
d

l
i

w
3
5
P
T
P,
R
M
M

,

+
R
E
t
n
e
r
r
u
c
e
r
/
d
e
c
n
a
v
d
a

r
e
c
n
a
c
l

a
i
r
t
e
m

s
h
t
n
o
m
y
t
r
i
h
t

l
i
t
n
u
s
h
t
n
o
m
e
e
r
h
t

t
n
e
m

l
l

o
r
n
e
s
’
t
n
e
i
t
a
p
t
s
a

l

e
h
t

r
e
t
f
a

b
a
m

i
l
i
t
n
S
f
o

i

P
O
H
C
-
R
d
n
a

L
C
B
L
D
e
v
i
t
i
s
o
p
-
1
L
-
D
P
d
n
a

s
t
n
e
i
t
a
p

o
t
p
u

,
s
t
n
e
i
t
a
p
n

i

S
F
P
n
a
d
e
M

i

l

/
e
o
z
o
r
t
e
L

h
t
i

w
s
t
n
e
i
t
a
p

)
8
1
>

(

s
t
l
u
d
A

l

a
i
r
t

I
I

e
s
a
h
P

A
S
U

d
e
t
r
a
t
s

t
o
N

7
4
3
6
6
3
6
0
T
C
N

s
t
n
e
i
t
a
p
n

i

S
F
D

r
a
e
y
-
e
e
r
h
T

n
o
i
t
a
d
a
R

i

h
t
i

w
s
t
n
e
i
t
a
p

)
8
1
>

(

t
l
u
d
A

l

a
i
r
t

I
I
I
/
I
I

e
s
a
h
P

a
d
a
n
a
C

g
n
i
t
i
u
r
c
e
r

,

e
v
i
t
c
A

5
5
1
9
5
1
4
0
T
C
N

I

P
F
r
e
t
f
a
s
h
t
n
o
m
0
5
S
F
P

,

i

b
n
i
t
u
r
b
a
a
c
A

l

h
t
i

w
s
t
n
e
i
t
a
p

)
8
1
>

(

t
l
u
d
A

l

a
i
r
t

I
I
I

e
s
a
h
P

y
n
a
m
r
e
G

g
n
i
t
i
u
r
c
e
r

,

e
v
i
t
c
A

2
9
1
7
9
1
5
0
T
C
N

,

l

n
o
i
t
e
e
d
-
p
7
1

:

i

g
n
w
o

l
l

o
f

l

x
e
p
m
o
c
r
o

,

n
o
i
t
a
t
u
m
-
3
5
P
T

-
o
r
h
c
e
r
o
m

r
o
3
(
e
p
y
t
o
y
r
a
k

r
o
2
n

i

s
n
o
i
t
a
r
r
e
b
a

l

a
m
o
s
o
m

)
s
e
s
a
h
p
a
t
e
m
e
r
o
m

-
t
a
e
r
t

t
s
a

l

e
h
t

r
e
t
f
a
s
y
a
d
0
3

l
i
t
n
u

i

e
n
b
a
r
a
t
y
C
h
t
i

w
n

i
l

d
a
m
e
n
a
u
S

l

e
l
c
y
c
t
n
e
m

n
o
i
t
a
n
b
m
o
c

i

h
t
i

w
y
p
a
r
e
h
t

i

e
n
b
a
r
a
t
y
C

r
o
y
p
a
r
e
h
t

-
o
n
o
m

s
a

-
d

l
i

w
h
t
i

w
S
D
M
d
e
c
n
a
v
d
A

3
5
P
T
e
p
y
t

f
o
y
p
a
r
e
h
t
n
o
i
t
a
n
b
m
o
c

i

)
4
2
9
6
-
N
R
L
A

(

r
o
L
M
A
y
r
o
t
c
a
r
f
e
r
/
d
e
s
p
a
e
r

l

/
-
o
n
o
m

f
o
y
t
i
l
i

l

b
a
r
e
o
t
d
n
a
y
t
e
f
a
S

n

i
l

d
a
m
e
n
a
u
S

l

h
t
i

w
s
t
n
e
i
t
a
p

)
8
1
>

(

t
l
u
d
A

l

a
i
r
t

I

e
s
a
h
P

A
S
U

g
n
i
t
i
u
r
c
e
r

,

e
v
i
t
c
A

2
7
9
9
0
9
2
0
T
C
N

y
r
e
v
e

,

e
t
a
r
n
o
i
s
s
i

m
e
r
e
t
e
p
m
o
C

l

n
o
i
t
a
n
b
m
o
C

i

t
n
a
t
u
m
-
3
5
P
T
)
8
1
>

(

t
l
u
d
A

l

a
i
r
t

I
I

e
s
a
h
P

i

a
n
h
C

s
u
t
a
t
s
n
w
o
n
k
n
U

6
1
9
3
2
0
4
0
T
C
N

r
a
e
y

b
a
m

i
l
i
t
n
S
f
o

i

P
O
H
C
-
R
d
n
a

h
t
i

w
n
o
i
t
a
t
u
m
3
5
P
h
t
i

w

n
o
i
s
s
e
r
p
x
e
1
L
-
D
P

e
n
o
o
t
p
u

,

e
t
a
r
e
s
n
o
p
s
e
r
e
t
e
p
m
o
C

l

n
o
i
t
a
n
b
m
o
C

i

s
t
n
e
i
t
a
p
L
C
B
L
D

)
8
1
>

(

t
l
u
d
A

l

a
i
r
t

I
I

e
s
a
h
P

d
e
n
fi
e
d
n
U

d
e
t
r
a
t
s

t
o
N

6
2
6
0
8
2
5
0
T
C
N

d
n
a
s
t
n
e
v
e
e
s
r
e
v
d
a
f
o
e
c
n
e
d
i
c
n

I

n

i

b
a
m
u
o
v
N

l

i

s
e
l
c
y
c
3
o
t
p
u

,

e
t
a
r
e
s
n
o
p
s
e
r

n
o
i
t
a
n
b
m
o
c

i

-
t
i
c
e
D
h
t
i

w

d
n
a
e
n
b
a

i

x
a
l
c
o
t
e
n
e
V

-
3
5
P
T
d
e
s
o
n
g
a
d
y
l
w
e
n

i

h
t
i

w
s
t
n
e
i
t
a
p

)
8
1
>

(

t
l
u
d
A

L
M
A
d
e
t
a
t
u
m

l

a
i
r
t

I

e
s
a
h
P

A
S
U

-
t
i
u
r
c
e
r

t
o
n

,

e
v
i
t
c
A

2
4
4
7
7
2
4
0
T
C
N

g
n

i

s
e
m
o
c
t
u
o
y
r
a
m

i
r
p
d
e
r
u
s
a
e
M

)
s
(
n
o
i
t
n
e
v
r
e
t
n

I

l

n
o
i
t
a
u
p
o
p
y
d
u
t
S

e
p
y
t
y
d
u
t
S

y
r
t
n
u
o
C

s
u
t
a
t
s
y
d
u
t
S

D

I

v
o
g
.
s
l
a
i
r
t
l
a
c
i
n

i
l

C

p
u
o
r
g

l

a
i
r
T

)
d
e
u
n
i
t
n
o
c
(

5
e
l
b
a
T

Vol:.(1234567890) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w 

Review

-
s
i
h
o
n
h
t
i

w
T
C
S
H
-
o

l
l

A
-
t
s
o
p

b
i
t
r
e
s
o
v
a
d
A

f
o
y
p
a
r
e
h
t

)
5
7
7
1
D
Z
A

(

-
i
l
c
a
P
h
t
i

w

l

e
x
a
t

-
3
5
P
T
d
e
c
n
a
v
d
a
h
t
i

w

)
0
2
<

(

c
i
r
t
s
a
g
g
n
i
r
o
b
r
a
h
n
o
i
t
a
t
u
m

t
n
a
t
s
i
s
e
r

,

a
m
o
n
i
c
r
a
c
o
n
e
d
a

-

l

m
u
n
i
t
a
p
/
U
F
-
5
e
n

i
l
-
t
s
r
fi
o
t

y
p
a
r
e
h
t
o
m
e
h
c
d
e
s
a
b

r
a
e
y
e
n
o
o
t
p
u

,
)
T
C
S
H
-
t
s
o
p

S
D
M
/
L
M
A
+
3
5
P
T
h
t
i

w

)
2
1
>

(

%
5
≥
s
t
s
a
b

l

(
e
s
p
a
e
r

l

f
o
e
c
n
e
d
i
c
n

I

α
-
n
o
r
e
f
r
e
t
n

I

s
t
l
u
d
a
g
n
u
o
y
d
n
a

,
t
l
u
d
a

,

d

l
i

h
C

l

a
i
r
t

I
I

e
s
a
h
P

i

a
n
h
C

g
n
i
t
i
u
r
c
e
r

,

e
v
i
t
c
A

9
7
5
0
3
1
6
0
T
C
N

T
C
S
H
r
e
t
f
a
S
D
M

r
o
L
M
A

t
p
o
p
a
t
e
n
e
r
p
E

-
i
t
i
c
a
z
A
h
t
i

w

)
6
4
2
-
R
P
A

(

f
o
y
p
a
r
e
h
t

e
n
d

i

-
l
o
f
S
D
M

r
o
L
M
A
d
e
t
a
t
u
m

T
C
S
A
g
n
w
o

i

l

s
k
e
e
w

i

t
h
g
e
r
e
t
f
a
s
t
n
e
i
t
a
p
n

i

R
R
O

n
o
i
t
a
n
b
m
o
C

i

s
t
l
u
d
a
g
n
u
o
y
d
n
a
n
e
r
d

l
i

h
C

l

a
i
r
t

I
I

e
s
a
h
P

a
e
r
o
K
h
t
u
o
S

l

d
e
t
e
p
m
o
C

9
2
3
8
4
4
2
0
T
C
N

d
e
t
a
t
u
m
3
5
P
T
h
t
i

w
s
t
n
e
i
t
a
p
n

i

S
F
R

n
o
i
t
a
n
b
m
o
C

i

3
5
P
T
h
t
i

w

)
8
1
>

(

s
t
l
u
d
A

l

a
i
r
t

I
I

e
s
a
h
P

A
S
U

l

d
e
t
e
p
m
o
C

1
9
2
1
3
9
3
0
T
C
N

s
e
m
o
c
t
u
o
y
r
a
m

i
r
p
d
e
r
u
s
a
e
M

)
s
(
n
o
i
t
n
e
v
r
e
t
n

I

l

n
o
i
t
a
u
p
o
p
y
d
u
t
S

e
p
y
t
y
d
u
t
S

y
r
t
n
u
o
C

s
u
t
a
t
s
y
d
u
t
S

D

I

v
o
g
.
s
l
a
i
r
t
l
a
c
i
n

i
l

C

p
u
o
r
g

l

a
i
r
T

)
d
e
u
n
i
t
n
o
c
(

5
e
l
b
a
T

i

s
g
n
d
n
fi
g
n
g
a
m

i

i

l

a
n
o
i
t

:
s
r
o
m
u
t
d
e
t
c
e
p
s
u
s
n
o
s
t
i
a
r
t
g
n
g
a
m

i

I

c
i
t
s
o
n
g
a
D

i

i

n
e
m
u
a
r
F
-
i
L
)
8
1
<

(
c
i
r
t
a
d
e
P

i

d
e

l
l

o
r
t
n
o
c
n
u
/
e
r
e
v
e
s

f
o
y
r
o
t

D
H
V
G

l

-
e
v
o
v
n

i

l

l

e
d
n
u
b
r
a
u
c
s
a
v
o
r
u
e
n
d
n
a

W
D
d
n
a
R
T
S
o
i
t
a
r

I

s
i
s
o
r
c
e
n
/
l
a
n
g
i
s

d
n
a
y
t
i
v
i
t
c
a
c
i
l

o
b
a
t
e
m
G
D
F

:
)
I
R
M

-
i
d
d
a
r
e
h
t
o
r
o

,
)
I
R
M
-
T
E
P
(
e
k
a
t
p
u

d
n
a

,
s
i
s
o
r
c
e
n

;
)
I
R
M
R
T
S
(

I

t
n
e
m

,
I

-

R
M
W
D

,
I

R
M

I

R
M
-
T
E
P
d
n
a

I

R
T
S
y
d
o
b

r
o
n
o
i
t
a
t
u
m
3
5
P
T
n
w
o
n
k
a

s
r
e
i
r
r
a
c
n
o
i
t
a
t
u
m
e
t
a
g

i
l

b
o

,

,
t
c
e
ff
e
s
s
a
m
y
t
i
e
n
e
g
o
r
e
t
e
h

l

a
n
g
S

i

l

e
o
h
w

f
o
s
t
s
e
t

i

g
n
y
r
r
a
c
s
d
e
r
d
n
k
e
m
o
r
d
n
y
s

i

p
u
o
r
g
-
e
g
n
S

l

i

c
i
t
s
o
n
g
a
d

i

y
d
u
t
s

t
o

l
i

p

-
n
y
s

i

n
e
m
u
a
r
F

i

L
h
t
i

w
s
t
n
e
i
t
a
p

r
u
o
f

r
o
f

r
a
e
y
r
e
t
f
a
r
a
e
y
e
m
o
r
d

s
n
a
c
s

l

a
u
n
n
a

I

R
M

s
r
e
b
m
e
m

,
s
r
e
i
r
r
a
c
n
o
i
t
a
t
u
m

c
i
s
s
a
l
c
g
n
i
t
e
e
m

s
e

i
l
i

m
a
f

f
o

e
t
a
g

i
l

b
o
d
n
a

,

a
i
r
e
t
i
r
c
S
F
L

3
5
p
e
n

i
l

m
r
e
G

(
e
m
o
r
d
n
y
s

i

n
e
m
u
a
r
F

i

L
d
e
n
fi
e
d
e
h
t

i

)
e
e
r
g
d
e
p
y
b
s
r
e
i
r
r
a
c

c
i
t
s
o
n
g
a
d

i

y
d
u
t
s

t
l
u
d
a
d
n
a
c
i
r
t
a
d
e
p
f
o
n
r
u
t
e
R

i

y
d
o
b
e
o
h
W

l

g
n
i
t
e
e
m
n
e
r
d

l
i

h
c
d
n
a
s
t
l
u
d
A

p
u
o
r
g
-
e
g
n
S

l

i

g
n

i

A
S
U

-
t
i
u
r
c
e
r

t
o
n

,

e
v
i
t
c
A

7
8
9
0
5
9
2
0
T
C
N

a
d
a
n
a
C

g
n
i
t
i
u
r
c
e
r

,

e
v
i
t
c
A

6
3
8
6
7
1
3
0
T
C
N

l

a
i
r
t
c
i
t
s
o
n
g
a
D

i

s
r
a
e
y
e
e
r
h
t

I

R
M

n
o
i
t
a
t
u
m
3
5
P

y
d
u
t
s

t
s
r
fi
e
h
t
g
n
i
r
u
d
r
e
c
n
a
c
f
o
e
c
n
e
d
i
c
n

I

y
d
o
b
e
o
h
W

l

h
t
i

w
s
t
n
e
i
t
a
p
d
o
r
a
e
y
1
7
–
5

l

l

a
i
r
t

I
I
I

e
s
a
h
P

e
c
n
a
r
F

l

d
e
t
e
p
m
o
C

6
8
0
4
6
4
1
0
T
C
N

l

e
s
n
o
p
s
e
r
e
t
e
p
m
o
c
/
l
a
i
t
r
a
p
n
w
o
h
s
y
l
s
u
o
v
e
r
p
h
t
i

i

 w

*

-

m
y
l

l
l

e
c
-
B
e
g
r
a

l

i

e
s
u
ff
D
L
C
B
L
D

,
s
t
n
e
v
E
e
s
r
e
v
d
A
r
o
f
a
i
r
e
t
i
r
C
y
g
o
o
n
m
r
e
T
n
o
m
m
o
C
E
A
C
T
C

l

i

,

i

a
m
e
k
u
e

l
c
i
t
y
c
o
h
p
m
y
l
c
i
n
o
r
h
C
L
L
C

,

b
a
m
i
x
u
t
i
R
d
n
a
e
n
i
t
s
u
m
a
d
n
e
B
R
B

,

i

a
m
e
k
u
e

l

i

l

d
o
e
y
m
e
t
u
c
A
L
M
A

d
n
a

,

i

e
d
m
a
h
p
s
o
h
p
o
l
c
y
C

,

i

e
n
b
a
r
a
d
u
F
R
C
F

l

,
r
o
t
p
e
c
e
r
n
e
g
o
r
t
s
E
R
E

,

i

n
o
i
t
a
d
a
R
m
a
e
B

l

a
n
r
e
t
x
E
R
B
E

,

i

g
n
g
a
m

i

e
c
n
a
n
o
s
e
r

c
i
t
e
n
g
a
m
d
e
t
h
g
e
w
-
n
o
i
s
u
ff
D

i

i

I

-

R
M
W
D

,
l

i

a
v
v
r
u
s
e
e
r
f
-
e
s
a
e
s
i
D
S
F
D

,

a
m
o
h
p

e
s
u
o
M
2
M
D
M

,

i

i

i

3
n
e
t
o
r
p
g
n
d
n
b
r
o
t
c
a
f
h
t
w
o
r
g
e
k
i
l
-
n

i
l

u
s
n

I

3
P
B
F
G

I

,

1

r
o
t
c
a
f
h
t
w
o
r
g
e
k
i
l
-
n

i
l

u
s
n

I

1
-
F
G

I

l

,
t
n
a
p
s
n
a
r
t

l
l

e
c
m
e
t
s

i

c
i
t
e
o
p
o
t
a
m
e
H
T
C
S
H

,

e
s
a
e
s
i
d
t
s
o
h
-
s
u
s
r
e
v
-
t
f
a
r
G
D
H
V
G

,

b
a
m
i
x
u
t
i
R

-
i
s
o
P
T
E
P

,
l

i

a
v
v
r
u
s

l
l

a
r
e
v
O
S
O

,

e
t
a
r
e
s
n
o
p
s
e
r
e
v
i
t
c
e
b
O
R
R
O

j

,

i

g
n
g
a
m

i

e
c
n
a
n
o
s
e
r
c
i
t
e
n
g
a
M

I

R
M

,
t
n
e
i
c
fi
o
r
p
r
i
a
p
e
r
h
c
t
a
m

s
i

M
P
R
M
M

,

l

e
m
o
r
d
n
y
s
c
i
t
s
a
p
s
y
d
o
e
y
M
S
D
M

l

,

l

g
o
o
m
o
h
2
e
t
u
n
m
e
b
u
o
d

l

i

n
o
i
s
r
e
v
n

i

u
a
T
t
r
o
h
S

I

R
T
S

,
l

i

a
v
v
r
u
s

e
e
r
f
-
e
s
p
a
e
R

l

S
F
R

,

e
n
o
s
i
n
d
e
r
P

,

e
n
i
t
s
i
r
c
n
V

i

,

n
i
c
i
b
u
r
o
x
o
D

,

i

e
d
m
a
h
p
s
o
h
p
o
l
c
y
C

,

b
a
m
i
x
u
t
i
R

P
O
H
C
-
R

,
l

i

a
v
v
r
u
s

e
e
r
f
-
n
o
i
s
s
e
r
g
o
r
P

S
F
P

,

y
h
p
a
r
g
o
m
o
t

n
o
i
s
s
i

m
e

n
o
r
t

y
r
e
v
o
c
e
r

Vol.:(0123456789) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review 

Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w

2.6.5   DNA damage response inhibitors

DNA damage response (DDR) pathway-targeting agents, such as poly(ADP-ribose) polymerase (PARP) inhibitors and 
ataxia telangiectasia and Rad3-related (ATR) inhibitors, have shown efficacy in preclinical models of LFS-associated 
malignancies, particularly in tumors with homologous recombination deficiency (HRD) [151–154].

2.6.6   Bruton’s tyrosine kinase inhibitor

Bruton’s tyrosine kinase (BTK) inhibitors are a class of targeted therapeutic agents that are generally considered in the 
treatment of B-cell malignancies, including B-cell chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma (MCL) 
[23, 155, 156]. BTKi is vital in B-cell receptor signaling, lymphocyte activation, and proliferation [157]. Small molecule 
BTK inhibitors irreversibly bind to the active site of BTK, thereby inhibiting its kinase activity and downstream signaling 
cascades, thus disrupting B-cell receptor signaling and promoting apoptosis of malignant B cells [158]. Ongoing research 
efforts try to evaluate the safety and effectiveness of BTK inhibitors, such as Acalabrutinib, in combination with other 
targeted therapies for LFS patients [156].

2.6.7   MDM2/X inhibitors

MDM2/X inhibitors disrupt the interaction between murine double minute 2 (MDM2) or its homolog murine double 
minute X (MDMX) and the tumor suppressor protein p53. This interaction basically leads to apoptosis evade. By inhibiting 
MDM2/X, these small molecule inhibitors restore p53 function, leading to cell cycle arrest, apoptosis, and tumor growth 
inhibition [159]. From several experimental agents of this class, Milademetan (DS-3032b), Sulanemadlin (ALRN-6924), 
and Brigimadlin (BI 907828) are extensively studied, showing promising results in the very early trials [146, 160–163].

2.6.8   Monoclonal antibodies

Monoclonal antibodies (mAbs) specifically target the antigens expressed on the surface of cancer cells or immune cells 
in the tumor microenvironment. Initiating various mechanisms of action, including antibody-dependent cellular cyto-
toxicity (ADCC), complement-dependent cytotoxicity (CDC), and blockade of tumor growth signaling pathways, several 
mAbs, such as Rituximab (anti-CD20), Obinutuzumab (anti-CD20), and Magrolimab (anti-CD47), are under investigation 
for LFS patients [164–167].

2.6.9   Arsenic trioxide

Arsenic trioxide is a cytotoxic agent primarily used in treatment-resistant leukemia [168]. Preclinical studies have provided 
strong evidence for the potential positive impact of arsenic on the survival of LFS patients [169]. Widely considered in 
early-phase trials of LFS treatment nowadays, arsenic trioxide is generally well-tolerated, but it could result in serious 
adverse effects, including QT interval prolongation, cardiac arrhythmias, hepatotoxicity, and neurotoxicity [170–172]. 
Close monitoring of cardiac function, electrolyte levels, and hepatic function is recommended during treatment with 
arsenic trioxide to minimize the risk of adverse events.

2.6.10   Other agents

Some existing medications and agents have also been explored as adjuvant LFS treatments. Metformin, a widely used 
oral antidiabetic agent, has attracted attention for its potential anticancer properties beyond its glucose-lowering effects 
[173, 174]. Metformin acts primarily by activating AMP-activated protein kinase (AMPK), a master regulator of cellular 
energy homeostasis, leading to inhibition of mTOR signaling, suppression of hepatic gluconeogenesis, and modulation 
of cellular metabolism [175, 176]. Although Metformin might not be the primary choice of treatment in LFS patients, 
given its efficacy in modulating the metabolic profile, the low cost, and accessibility, it could be considered as a pre-
ventive agent, especially in individuals with metabolic disorders or obesity-associated cancers [177, 178]. Likewise, 
nicotinamide riboside, the precursor of nicotinamide adenine dinucleotide  (NAD+), could lead to increased  NAD+ levels, 

Vol:.(1234567890)Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w 

Review

thereby activating sirtuins and other  NAD+-dependent enzymes involved in DNA repair, chromatin remodeling, and 
mitochondrial function [179–181]. Previous studies have suggested that nicotinamide riboside enhances cellular stress 
resistance, inhibiting tumorigenesis and promoting cancer cell apoptosis [182, 183].

The chemopreventive approaches, using medications such as Tamoxifen and Raloxifene, have also been proven effec-

tive [184], but are still controversial due to their adverse effects and low patient compliance.

2.7   Challenges

LFS, and the broader context of TP53 mutation research, face various challenges affecting both patients and healthcare 
providers, including:

2.7.1   Development of targeted therapies

Although TP53 is one of the most frequently mutated genes in cancer, developing therapies that effectively target mutant 
TP53 has proven difficult.

2.7.2   Variants of uncertain significance

Variants of uncertain significance (VUS), the mutations that their impact – whether pathogenic or benign – on the molecu-
lar function and cancer risk is not fully understood, impose clinical challenges in genetic counseling, risk assessment, 
potential surveillance protocols, and decision-making for both patients and healthcare providers [185]. Guidelines lack 
clear recommendations for this population, as the cancer risk associated with VUS is uncertain and lacks sufficient data. 
Although in silico models deliver useful predictions, these models are generally not sufficient to guide clinical decision-
making [186]. Meanwhile, the Clinical Genome Resource (ClinGen) TP53 variant curation expert panel has introduced 
a set of guidelines launched to classify TP53 variants, provide consistent and reliable interpretations of their clinical 
significance, and help distinguish pathogenic mutations from benign variants and VUS [187, 188].

2.7.3   Germline vs somatic TP53 mutations

Differentiating between germline and somatic mutations is one of the major challenges with TP53 mutations identified 
through NGS. While the inherited germline mutations lead to LFS, somatic mutations are not heritable. When a TP53 
mutation is detected via an NGS panel, it is not immediately clear whether it is germline or somatic–possibly originat-
ing from clonal hematopoiesis of indeterminate potential (CHIP) [115]. Misinterpretation of somatic TP53 mutations as 
germline can lead to unnecessary cancer surveillance in individuals who do not have LFS. Moreover, the detection of low 
variant allele frequencies (VAF) in TP53 mutations adds complexity to the interpretation. VAF represents the proportion 
of sequencing reads containing a variant, and low VAFs suggest somatic mutations arising from clonal hematopoiesis 
rather than true germline mutations [189].

NGS panels often include TP53 to identify mutations for tumor profiling or assessing hereditary cancer risk. In older 
adults, however, or those with CHIP, TP53 mutations detected in blood or bone marrow samples may be false positives 
for germline testing, leading to misdiagnosis [190]. Consequently, patients with a CHIP-related TP53 mutation might be 
unnecessarily subjected to LFS cancer surveillance for solid tumors due to the miscalculated cancer risk [115]. Moreover, 
TP53 mutations with low VAF may lead to clinical dilemmas for testing family members, as the mutation may be somatic 
rather than germline.

2.7.4   Overlapping syndromes and genetic mimics

LFS overlaps with some other cancer-predisposing syndromes, complicating the diagnosis and risk assessment. CHEK2 
(checkpoint kinase two) and BRCA1/2 (breast cancer genes 1 and 2) are among the most famous LFS-mimicking muta-
tions. For instance, mutations in CHEK2—also a tumor suppressor gene—referred to as the ‘CHEK2-associated Li–Frau-
meni syndrome’ or ‘Li-Fraumeni syndrome 2’, are occasionally misclassified as a subtype of LFS [191]. CHEK2 encodes a 
serine/threonine kinase regulating the cellular response to DNA damage, and its mutations result in a tumor predisposi-
tion syndrome, associated with a moderately increased risk for later-onset development of less broad cancers, including 
breast, prostate, and gastrointestinal tumors [191–193]. Moreover, CHEK2 is considered a low-penetrance gene compared 

Vol.:(0123456789)Review 

Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w

to TP53, suggesting that not all individuals with CHEK2 mutations will develop cancer [194]. Studies have highlighted 
the clear and significant distinctions in the clinical presentations of TP53 and CHEK2 pathogenic variant carriers and the 
lack of association between CHEK2 and TP53-related LFS [195]. While both TP53 and CHEK2 are involved in DNA repair 
and tumor suppression, CHEK2 mutations do not confer the same features as LFS, and since it could lead to inappropriate 
management and suboptimal surveillance, their classification as an LFS subtype is generally discouraged.

2.7.5   Limited long‑term data

As only a small proportion of LFS patients show long-term adherence to the surveillance protocols, the long-term follow-
up data on LFS patients, particularly in relation to the effectiveness of surveillance programs and therapeutic interven-
tions, is limited, negatively affecting the development of clinical evidence-based prevention and treatment guidelines 
[196]. The impact of intensive screening on patient survival and quality of life over long periods is not fully understood 
so far, and data on the long-term risks and complications, including the risks of radiation exposure from frequent imag-
ing, are rare.

2.7.6   Cancer surveillance and overdiagnosis

Lifelong cancer surveillance is essential for patients with confirmed pathogenic TP53 mutations. However, striking the 
right balance between early cancer detection and overdiagnosis still remains a significant challenge [197]. Extensive 
screening protocols, often including annual whole-body MRIs, can lead to false-positive results or detection of indolent 
cancers that may never progress to a clinically significant disease. Meanwhile, some patients may not follow the full 
range of recommended screenings due to a lack of resources or understanding of the significance of TP53 mutations, 
potentially leading to missed early detection opportunities.

2.7.7   Access to care

Access to genetic testing and specialized cancer care for individuals at risk of or diagnosed with LFS varies widely by 
region and healthcare system [198]. In some areas, the availability of genetic testing, surveillance, and specialized treat-
ments may be limited, creating disparities in patient outcomes. The cost of genetic testing, preventive surgeries, or 
frequent cancer screenings can be prohibitive for some families, potentially leaving patients with suboptimal care or 
late-stage cancer diagnoses. Moreover, not all clinicians are fully aware of LFS or the need for comprehensive genetic 
testing in patients with a family history of cancers, leading to inadequate care in some cases.

2.7.8   The complexity of multidisciplinary care

The management of LFS requires a multidisciplinary approach, involving geneticists, oncologists, surgeons, radiologists, 
psychologists, and other specialists. Coordinating care across these domains can be difficult, particularly in healthcare 
settings without established protocols for hereditary cancer syndromes.

2.7.9   Psychosocial burden

The psychosocial challenges faced by individuals with LFS are significant, as it often affects multiple generations within 
a family, leading to fear of developing cancer and anxiety about passing the mutation on to offspring [199]. The ongoing 
stress of living with an increased risk of cancer, along with the emotional toll of frequent surveillance, can be overwhelm-
ing for patients and their families.

3   Future directions

Advancements in genomic technologies have facilitated the identification of novel therapeutic agents and the devel-
opment of targeted therapies for LFS-associated malignancies. Novel cancer therapies, including various cancer immu-
notherapy modalities, checkpoint inhibitors, adoptive cell therapies, and various agents and methods of targeted 
therapy, hold promise in improving treatment outcomes and reducing cancer burden in individuals with LFS (Table 5). 

Vol:.(1234567890)Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w 

Review

Additionally, ongoing research efforts aim to elucidate the molecular mechanisms underlying LFS pathogenesis and 
identify potential biomarkers for early detection and risk stratification. Longitudinal cohort studies and population-
based registries are essential in clarifying the natural history, risk factors of recurrence, and outcomes associated with 
LFS. Furthermore, molecular epidemiological studies leveraging genomic technologies and bioinformatics analyses offer 
insights into the genetic determinants, mutational signatures, and clonal evolution patterns underlying LFS-associated 
tumorigenesis, guiding precision medicine approaches and targeted interventions tailored to the unique molecular 
profiles of individual tumors.

4   Conclusions

Li-Fraumeni Syndrome poses significant challenges in clinical management due to its diverse spectrum of associated 
malignancies and the need for lifelong surveillance and interventions. A comprehensive understanding of the molecular 
basis, clinical manifestations, diagnostic criteria, screening strategies, and management options for LFS is crucial for opti-
mizing patient care and outcomes. Continued research efforts aimed at clarifying the underlying mechanisms, optimum 
and effective surveillance strategies, and developing targeted therapeutic approaches are essential for improving the 
prognosis of individuals affected.

Acknowledgements  Parts of the figures were created using Servier Medical Art, licensed under CC BY 4.0 (https:// creat iveco mmons. org/ licen 
ses/ by/4. 0/).

Author contributions  MSH: Conceptualization, Data Curation, Visualization, Writing—Original Draft and Review & Editing.

Funding  None.

Data availability  All data generated during this study are included in the published article.

Declarations 

Ethics approval and consent to participate  Not applicable.

Consent for publication  Not applicable.

Competing interests  The authors declare no competing interests.

Open Access   This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which 
permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to 
the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You 
do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party 
material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If 
material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds 
the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco 
mmons. org/ licen ses/ by- nc- nd/4. 0/.

References

  1.  Ganguly A, Chen Z. Li-Fraumeni syndrome. Mol Pathol Clin Pract. 2016. https:// doi. org/ 10. 1007/ 978-3- 319- 19674-9_ 28.
  2.  Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. Ann Int Med. 1969;71(4):747–52. https:// doi. org/ 10. 7326/ 

0003- 4819- 71-4- 747.

  3.  Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, et al. A cancer family syndrome in twenty-four kindreds. Cancer 

Res. 1988;48(18):5358–62.

  4.  Gargallo P, Yáñez Y, Vanessa S, Juan A, Torres B, Balaguer J, et al. Li–Fraumeni syndrome heterogeneity. Clin Trans Oncol. 2020;22:978–88.
  5.  Giacomazzi Cristina R, Giacomazzi J, Netto Cristina BO, Santos-Silva P, Selistre Simone G, Maia AL, et al. Pediatric cancer and Li-Fraumeni/

Li-Fraumeni-like syndromes: a review for the pediatrician. Rev Assoc Med Bras. 2015;61:282–9.

  6.  Hendrickson PG, Luo Y, Kohlmann W, Schiffman J, Maese L, Bishop AJ, et al. Radiation therapy and secondary malignancy in Li-Fraumeni 

syndrome: a hereditary cancer registry study. Cancer Med. 2020;9(21):7954–63.

  7.  Petry V, Bonadio Renata C, Cagnacci Allyne QC, Senna Luiz Antonio L, Campos RNG, Cotti GC, et al. Radiotherapy-induced malignancies 

in breast cancer patients with TP53 pathogenic germline variants (Li–Fraumeni syndrome). Fam Cancer. 2020;19:47–53.

  8.  Correa H. Li–Fraumeni syndrome. J Pediat Genet. 2016. https:// doi. org/ 10. 1055/s- 0036- 15797 59.

Vol.:(0123456789)Review 

Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w

  9.  Zeng HH, Yang Z, Qiu YB, Bashir S, Li Y, Xu M. Detection of a novel panel of 24 genes with high frequencies of mutation in gastric 
cancer based on next-generation sequencing. World J Clin Cases. 2022;10(15):4761–75. https:// doi. org/ 10. 12998/ wjcc. v10. i15. 4761.
  10.  Mijit M, Caracciolo V, Melillo A, Amicarelli F, Giordano A. Role of p53 in the Regulation of Cellular Senescence. Biomolecules. 2020. 

https:// doi. org/ 10. 3390/ biom1 00304 20.

  11.  Patil MR, Bihari A. A comprehensive study of p53 protein. J Cell Biochem. 2022;123(12):1891–937. https:// doi. org/ 10. 1002/ jcb. 30331.
  12.  Marei HE, Althani A, Afifi N, Hasan A, Thomas C, Giacomo P, et al. p53 signaling in cancer progression and therapy. Cancer cell Int. 

2021;21(1):1–15.

  13.  Yan S, Varda R, Ronit A-G. Gain-of-function mutant p53: all the roads lead to tumorigenesis. Int J Mol Sci. 2019;20(24):6197.
  14.  Zhou X, Hao Q, Hua L. Mutant p53 in cancer therapy—the barrier or the path. J Mol Cell Biol. 2018;11(4):293–305. https:// doi. org/  

10. 1093/ jmcb/ mjy072.

  15.  Hainaut P. TP53: coordinator of the processes that underlie the hallmarks of cancer. p53 in the Clinics. Springer 2012. p. 1–23.
  16.  Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell. Cell Death Different. 2019;26(2):199–212. https:// doi. 

org/ 10. 1038/ s41418- 018- 0246-9.

  17.  Xiaohua C, Zhang Taotao Su, Wei DZ, Dapeng Z, Xiaodong J, et al. Mutant p53 in cancer: from molecular mechanism to therapeutic 

modulation. Cell Death Dis. 2022;13(11):974. https:// doi. org/ 10. 1038/ s41419- 022- 05408-1.

  18.  Stengel A, Schnittger S, Weissmann S, Kuznia S, Kern W, Kohlmann A, et al. TP53 mutations occur in 15.7% of ALL and are asso-
ciated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. Blood. 2014;124(2):251–8. https:// doi. org/ 10. 1182/ 
blood- 2014- 02- 558833.

  19.  Teroerde M, Nientiedt C, Duensing A, Hohenfellner M, Stenzinger A, Duensing S. Revisiting the role of p53 in prostate cancer. 2021.
  20.  D’Orazio JA. Inherited cancer syndromes in children and young adults. J Pediatr Hematol Oncol. 2010;32(3):195–228. https:// doi. org/ 

10. 1097/ MPH. 0b013 e3181 ced34c.

  21.  Baugh EH, Hua K, Levine AJ, Bonneau RA, Chan CS. Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death 

Different. 2018;25(1):154–60. https:// doi. org/ 10. 1038/ cdd. 2017. 180.

  22.  Hiroko N, Kinga S, Hidetaka Y, Yuji I, Marta G, Jelena Š, et al. Non-CpG sites preference in G:C > A: t transition of TP53 in gastric cancer 
of Eastern Europe (Poland, Romania and Hungary) compared to East Asian countries (China and Japan). Genes Environ. 2023;45(1):1. 
https:// doi. org/ 10. 1186/ s41021- 022- 00257-y.

  23.  Campo E, Cymbalista F, Ghia P, Jäger U, Pospisilova S, Rosenquist R, et al. TP53 aberrations in chronic lymphocytic leukemia: an overview 
of the clinical implications of improved diagnostics. Haematologica. 2018;103(12):1956–68. https:// doi. org/ 10. 3324/ haema tol. 2018. 
187583.

  24.  Silwal-Pandit L, Vollan Hans KM, Suet-Feung C, Rueda OM, McKinney S, Osako T, et al. TP53 mutation spectrum in breast cancer is subtype 

specific and has distinct prognostic relevance. Clin Cancer Res. 2014;20(13):3569–80. https:// doi. org/ 10. 1158/ 1078- 0432. ccr- 13- 2943.

  25.  Ozaki T, Nakagawara A. Role of p53 in cell death and human cancers. Cancers. 2011;3(1):994–1013. https:// doi. org/ 10. 3390/ cance rs301 

0994.

  26.  Aubrey BJ, Kelly GL, Ana J, Herold MJ, Andreas S. How does p53 induce apoptosis and how does this relate to p53-mediated tumour 

suppression? Cell Death Different. 2018;25(1):104–13. https:// doi. org/ 10. 1038/ cdd. 2017. 169.

  27.  Végran F, Rebucci M, Chevrier S, Cadouot M, Boidot R, Lizard-Nacol S. Only missense mutations affecting the DNA binding domain of 
p53 influence outcomes in patients with breast carcinoma. PLoS ONE. 2013;8(1): e55103. https:// doi. org/ 10. 1371/ journ al. pone. 00551 
03.

  28.  Fischer NW, Ma YV, Gariépy J. Emerging insights into ethnic-specific TP53 germline variants. J Natl Cancer Inst. 2023;115(10):1145–56. 

https:// doi. org/ 10. 1093/ jnci/ djad1 06.

  29.  Stieg DC, Parris JLD, Yang THL, Mirji G, Reiser SK, Murali N, et al. The African-centric P47S variant of TP53 confers immune dysregulation 
and impaired response to immune checkpoint inhibition. Cancer Res Commun. 2023;3(7):1200–11. https:// doi. org/ 10. 1158/ 2767- 9764. 
crc- 23- 0149.

  30.  Pinto EM, Figueiredo BC, Chen W, Galvao HCR, Formiga MN, Mcbv F, et al. XAF1 as a modifier of p53 function and cancer susceptibility. 

Sci Adv. 2020. https:// doi. org/ 10. 1126/ sciadv. aba32 31.

  31.  de Vries A, Flores ER, Miranda B, Hsieh HM, van Oostrom CT, Sage J, et al. Targeted point mutations of p53 lead to dominant-negative 

inhibition of wild-type p53 function. Proc Natl Acad Sci USA. 2002;99(5):2948–53. https:// doi. org/ 10. 1073/ pnas. 05271 3099.

  32.  Chiang YT, Chien YC, Lin YH, Wu HH, Lee DF, Yu YL. The function of the mutant p53–R175H in cancer. Cancers. 2021. https:// doi. org/ 10. 

3390/ cance rs131 64088.

  33.  Muller Patricia AJ, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25(3):304–17. 

https:// doi. org/ 10. 1016/j. ccr. 2014. 01. 021.

  34.  Penkert J, Strüwe FJ, Dutzmann CM, Doergeloh BB, Montellier E, Freycon C, et al. Genotype–phenotype associations within the Li-
Fraumeni spectrum: a report from the German Registry. J Hematol Oncol. 2022;15(1):107. https:// doi. org/ 10. 1186/ s13045- 022- 01332-1.
  35.  Kratz CP, Freycon C, Maxwell KN, Nichols KE, Schiffman JD, Evans DG, et al. Analysis of the Li-Fraumeni spectrum based on an international 
germline TP53 variant data set: an international agency for research on cancer TP53 database analysis. JAMA Oncol. 2021;7(12):1800–5. 
https:// doi. org/ 10. 1001/ jamao ncol. 2021. 4398.

  36.  Fortuno C, Pesaran T, Mester J, Dolinsky J, Yussuf A, McGoldrick K, et al. Genotype-phenotype correlations among TP53 carriers: literature 
review and analysis of probands undergoing multi-gene panel testing and single-gene testing. Cancer Genet. 2020. https:// doi. org/ 10. 
1016/j. cance rgen. 2020. 09. 002.

  37.  Pinto EM, Zambetti GP. What 20 years of research has taught us about the TP53 p.R337H mutation. Cancer. 2020;26(21):4678–86. https:// 

doi. org/ 10. 1002/ cncr. 33143.

  38.  Huaying Hu, Jingping L, Xinbin L, Shuju Z, Li Haibo Lu, Renbin, et al. Genetic and functional analysis of a Li Fraumeni syndrome family 

in China. Sci Rep. 2016;6(1):20221. https:// doi. org/ 10. 1038/ srep2 0221.

  39.  Amanda K, Heather S, Michèle R. Common and founder mutations for monogenic traits in sub-saharan African populations. Annu Rev 

Genomics Hum Genet. 2018;19:149–75.

  40.  Charames George S, Peter S, Nicholas W. Clinical and genetic evidence and population evidence. Clin DNA Variant Interpret. 2021;59:87.

Vol:.(1234567890)Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w 

Review

  41.  Ayed A, Hupp T, Olivier M, Petitjean A, de Caron FC, Hainaut P. TP53 mutations in human cancers: selection versus mutagenesis. In: Ayeda 

A, Theodore H, editors. p53. Boston MA: Springer, US; 2010. p. 1–18.

  42.  Malkin D. Li–Fraumeni syndrome. In: Gary DH, Tobias E, editors. Adrenocortical Carcinoma. New York: Springer; 2010. p. 172–91.
  43.  Rocca V, Blandino G, D’Antona L, Iuliano R, Di Agostino S. Li–Fraumeni syndrome: mutation of TP53 is a biomarker of hereditary predis-

position to tumor: new insights and advances in the treatment. Cancers. 2022;14(15):3664.

  44.  Amadou A, Achatz Maria IW, Hainaut P. Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases 

of Li–Fraumeni syndrome. Curr Opin Oncol. 2018;30(1):23–9.

  45.  Guha T, Malkin D. Inherited TP53 Mutations and the Li-Fraumeni syndrome. Cold Spring Harbor Perspect Med. 2017. https:// doi. org/ 10. 

1101/ cshpe rspect. a0261 87.

  46.  Schneider K, Zelley K, Nichols Kim E, Garber J. Li-fraumeni syndrome. 2019.
  47.  Chan CS. Prevalence and penetrance of Li-Fraumeni cancer predisposition syndrome. Curr Opin Syst Biol. 2017;1:48–53. https:// doi. org/ 

10. 1016/j. coisb. 2016. 12. 015.

  48.  Shin Seung J, Dodd-Eaton EB, Gang P, Bojadzieva J, Chen J, Amos Christopher I, et al. Penetrance of different cancer types in families 

with Li-Fraumeni syndrome: a validation study using multicenter cohorts. Cancer Res. 2020;80(2):354–60.

  49.  Rana HQ, Gelman R, LaDuca H, McFarland R, Dalton E, Thompson J, et al. Differences in TP53 mutation carrier phenotypes emerge from 

panel-based testing. J Natl Cancer Inst. 2018;110(8):863–70. https:// doi. org/ 10. 1093/ jnci/ djy001.

  50.  Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect 

Biol. 2010;2(1): a001008. https:// doi. org/ 10. 1101/ cshpe rspect. a0010 08.

  51.  Rogoża-Janiszewska E, Malińska K, Górski B, Scott RJ, Cybulski C, Kluźniak W, et al. Prevalence of germline TP53 variants among 
early-onset breast cancer patients from Polish population. Breast cancer (Tokyo, Japan). 2021;28(1):226–35. https:// doi. org/ 10. 1007/ 
s12282- 020- 01151-7.

  52.  Sabine G, Juliane R, Heide H, Nicole P, Melanie B, Christine B, et al. TP53 germline mutations in the context of families with hereditary 
breast and ovarian cancer: a clinical challenge. Arch Gynecol Obstet. 2021;303(6):1557–67. https:// doi. org/ 10. 1007/ s00404- 020- 05883-x.
  53.  de Andrade KC, Lee EE, Tookmanian EM, Kesserwan CA, Manfredi JJ, Hatton JN, et al. The TP53 database: transition from the international 
agency for research on cancer to the us national cancer institute. Cell Death Differentiation. 2022;29(5):1071–3. https:// doi. org/ 10. 1038/ 
s41418- 022- 00976-3.

  54.  The TP53 Database (R20) 2019 https:// tp53. isb- cgc. org. Accessed 15 April 2024
  55.  Chompret A, Brugières L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A, et al. P53 germline mutations in childhood cancers and cancer 

risk for carrier individuals. Br J Cancer. 2000;82(12):1932–7. https:// doi. org/ 10. 1054/ bjoc. 2000. 1167.

  56.  Nandikolla AG, Venugopal S, Anampa J. Breast cancer in patients with Li-Fraumeni syndrome—a case-series study and review of litera-

ture. Breast cancer (Dove Medical Press). 2017;9:207–15. https:// doi. org/ 10. 2147/ bctt. s1342 41.

  57.  de Andrade KC, Frone Megan N, Wegman-Ostrosky T, Khincha Payal P, Kim J, Amadou A, et al. Variable population prevalence estimates 

of germline TP53 variants: A gnomAD-based analysis. Hum Mutat. 2019;40(1):97–105.

  58.  Henriett B, Anikó B, Vince G, Erika S, János P, Attila P. Challenging interpretation of germline TP53 variants based on the experience of a 

national comprehensive cancer centre. Sci Rep. 2023;13(1):14259.

  59.  Kamps R, Brandão Rita D, van den Bosch BJ, Paulussen Aimee DC, Xanthoulea S, Blok Marinus J, et al. Next-generation sequencing in 

oncology: genetic diagnosis, risk prediction and cancer classification. Int J Mol Sci. 2017;18(2):308.

  60.  Robson Mark E, Bradbury Angela R, Arun B, Domchek Susan M, Ford James M, Hampel Heather L, et al. American society of clinical 

oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2015;33(31):3660–7.

  61.  Valdez Jessica M, Nichols Kim E, Kesserwan C. Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposi-

tion. British J Haematol. 2017;176(4):539–52.

  62.  Giacomazzi J, Selistre SG, Rossi C, Alemar B, Santos-Silva P, Pereira FS, et al. Li-Fraumeni and Li-Fraumeni—like syndrome among children 

diagnosed with pediatric cancer in Southern Brazil. Cancer. 2013;119(24):4341–9.

  63.  Sorrell April D, Espenschied Carin R, Culver Julie O, Weitzel JN. Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome: current 

status of clinical applications and future directions. Mol Diagn Ther. 2013;17:31–47.

  64.  Ognjanovic S, Olivier M, Bergemann T, Hainaut P. Sarcomas in TP53 germline mutation carriers. Cancer. 2012;118(5):1387–96. https:// 

doi. org/ 10. 1002/ cncr. 26390.

  65.  Ottaviani G, Jaffe N. The etiology of osteosarcoma. Pediat Adoles Osteosarcoma. 2010;15:32.
  66.  Pablo G, Yania Y, Antonio J, Vanessa S, Julia B, Bárbara T, et al. Ewing sarcoma predisposition. Pathol Oncol Res. 2020;26:2057–66.
  67.  Camejo N, Castillo C, Richter L, Massia María N, Artagaveytia N, Neffa F, et al. Li-Fraumeni syndrome: clinical case study and literature 

survey. Revista Uruguaya de Medicina Interna. 2018;3(3):20–6.

  68.  Susanne M, David G, Thomas W, Ulf K, Åke B, Håkan O. Prevalence of germline TP53 mutations and history of Li–Fraumeni syndrome in 
families with childhood adrenocortical tumors, choroid plexus tumors, and rhabdomyosarcoma: a population-based survey. Pediatr 
Blood Cancer. 2012;59(5):846–53.

  69.  Sabater-Marco V, Ferrando-Roca F, Morera-Faet A, García-García JA, Bosch Sandra B, López-Guerrero JA. Primary cutaneous leiomyosar-
coma arising in a patient with Li-Fraumeni syndrome: a neoplasm with unusual histopathologic features and loss of heterozygosity at 
TP53 gene. Am J Dermatopathol. 2018;40(3):225–7.

  70.  Hirofumi W, Fumiyoshi F, Toru M, Yayoi A, Tetsuya N, Masanobu T, et al. Comprehensive genomic profiling of a unique liposarcoma arising 

in a patient with Li–Fraumeni syndrome and the novel detection of c-myc amplification: a case report. Diagn Pathol. 2022;17(1):1–6.

  71.  Barbosa Oséias V, Reiriz André B, Boff Ricardo A, Oliveira Willian P, Rossi L. Angiosarcoma in previously irradiated breast in patient with 

Li-Fraumeni syndrome. a case report. Sao Paulo Med J. 2014;133:151–3.

  72.  Evans D, Gareth R, Huson Susan M, Birch JM. Malignant peripheral nerve sheath tumours in inherited disease. Clin Sarcoma Res. 

2012;2(1):1–5.

  73.  Legnani PE. GI stromal tumors. Mount Sinai Expert Guides. 2014;270:8.
  74.  Pantziarka P. Primed for cancer: Li Fraumeni syndrome and the pre-cancerous niche. ecancermedicalscience. 2015. https:// doi. org/ 10. 

3332/ ecanc er. 2015. 541.

Vol.:(0123456789)Review 

Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w

  75.  Nikita C, Behrang A, Ibarra-Rovira Juan J, Blair Katherine J, Moseley Tanya W, Taher A, et al. Li-Fraumeni syndrome and whole-body MRI 
screening: screening guidelines, imaging features, and impact on patient management. Am J Roentgenol. 2021;216(1):252–63.
  76.  Gabriela KM, Lester SC, Bowman T, Stokes SM, Taneja KL, Garber JE, et al. Histopathologic features of breast cancer in Li–Fraumeni syn-

drome. Modern Pathol. 2021;34(3):542–8. https:// doi. org/ 10. 1038/ s41379- 020- 0610-4.

  77.  Masciari S, Dillon DA, Rath M, Robson M, Weitzel JN, Balmana J, et al. Breast cancer phenotype in women with TP53 germline mutations: 
a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat. 2012;133(3):1125–30. https:// doi. org/ 10. 1007/ s10549- 012- 1993-9.
  78.  Verdial FC, Etzioni R, Duggan C, Anderson BO. Demographic changes in breast cancer incidence, stage at diagnosis and age associated 

with population-based mammographic screening. J Surg Oncol. 2017;115(5):517–22. https:// doi. org/ 10. 1002/ jso. 24579.

  79.  Sandoval Renata L, Polidorio N, Leite Ana CR, Cartaxo M, Pisani Janina P, Quirino Carla V, et al. Breast cancer phenotype associated with 
li-fraumeni syndrome: a Brazilian cohort enriched by TP53 p.R337H Carriers. Front Oncol. 2022. https:// doi. org/ 10. 3389/ fonc. 2022. 836937.
  80.  Khincha PP, Best AF, Fraumeni JF Jr, Loud JT, Savage SA, Achatz MI. Reproductive factors associated with breast cancer risk in Li-Fraumeni 

syndrome. Euro J Cancer. 2019;116:199–206. https:// doi. org/ 10. 1016/j. ejca. 2019. 05. 005.

  81.  Olsson H, Magnusson S, Bladström A. Lower breast cancer survival in mothers of children with a malignancy: a national study. Br J Cancer. 

2008;98(11):1876–8. https:// doi. org/ 10. 1038/ sj. bjc. 66043 50.

  82.  Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, et al. Early onset HER2-positive breast cancer is 

associated with germline TP53 mutations. Cancer. 2011;118(4):908–13. https:// doi. org/ 10. 1002/ cncr. 26377.

  83.  Sasaki R, Horimoto Y, Saeki H, Sato S, Sano K, Shikama N, et al. Lessons learned in practice with Li-Fraumeni syndrome: LFS-related breast 

cancer treatment strategy and establishment of a surveillance system. Juntendo Med J. 2022;68(4):405–12.

  84.  Carta R, Del Baldo G, Miele E, Po A, Besharat ZM, Nazio F, et al. Cancer predisposition syndromes and medulloblastoma in the molecular 

Era. Front Oncol. 2020;10: 566822. https:// doi. org/ 10. 3389/ fonc. 2020. 566822.

  85.  Sloan EA, Hilz S, Gupta R, Cadwell C, Ramani B, Hofmann J, et al. Gliomas arising in the setting of Li-Fraumeni syndrome stratify into 
two molecular subgroups with divergent clinicopathologic features. Acta Neuropathol. 2020;139(5):953–7. https:// doi. org/ 10. 1007/ 
s00401- 020- 02144-8.

  86.  Tabori U, Anne-Marie L, Ellezam B, Anne-Sophie C. Cancer predisposition in children with brain tumors. Pediatric Neuro-Oncol. 2015. 

https:// doi. org/ 10. 1007/ s00401- 020- 02144-8.

  87.  Orr BA, Clay MR, Pinto EM, Kesserwan C. An update on the central nervous system manifestations of Li–Fraumeni syndrome. Acta Neu-

ropathol. 2020. https:// doi. org/ 10. 1007/ s00401- 019- 02055-3.

  88.  Ceglie G, Del Baldo G, Agolini E, Rinelli M, Cacchione A, Del Bufalo F, et al. Cancer predisposition syndromes associated with pediatric 

high-grade gliomas. Front Pediatr. 2020;8: 561487. https:// doi. org/ 10. 3389/ fped. 2020. 561487.

  89.  McEvoy M, Robison N, Manley P, Yock T, Konopka K, Brown RE, et al. Successful treatment of recurrent Li-Fraumeni syndrome-related 

choroid plexus carcinoma. J Pediatr Hematol Oncol. 2017;39(8):e473–5. https:// doi. org/ 10. 1097/ mph. 00000 00000 000965.

  90.  Smith CJ, Perfetti TA, Chokshi C, Venugopal C, Ashford J, Singh SK. Risk factors for glioblastoma are shared by other brain tumor types. 

Human Exper Toxicol. 2024. https:// doi. org/ 10. 1177/ 09603 27124 12417 96.

  91.  Onciul R, Brehar FM, Toader C, Covache-Busuioc RA, Glavan LA, Bratu BG, et al. Deciphering glioblastoma: fundamental and novel insights 
into the biology and therapeutic strategies of gliomas. Curr Issues Mol Biol. 2024;46(3):2402–43. https:// doi. org/ 10. 3390/ cimb4 60301 
53.

  92.  Mahapatra S, Amsbaugh MJ. Medulloblastoma. StatPearls: StatPearls Publishing LLC.; 2024.
  93.  Petr Elisabeth J, Else T. Genetic predisposition to endocrine tumors: diagnosis, surveillance and challenges in care. Seminars Oncol. 

2016;43(5):582–90. https:// doi. org/ 10. 1053/j. semin oncol. 2016. 08. 007.

  94.  Lee RH, Wai KC, Chan JW, Ha PK, Kang H. Approaches to the management of metastatic adenoid cystic carcinoma. Cancers. 2022. https:// 

doi. org/ 10. 3390/ cance rs142 25698.

  95.  Bondy S, Tajzler C, Hotte SJ, Kapoor A, Zbuk K, Lalani AA. Genomic and clinical correlates of adrenocortical carcinoma in an adult patient 

with li-fraumeni syndrome: a case report. Curr Oncol. 2020;28(1):226–32. https:// doi. org/ 10. 3390/ curro ncol2 80100 25.

  96.  Røe OD, Oppegaard PA, Revheim ME, Svindland A. Adrenocortical carcinoma mimicking lung cancer and responding to vinorelbine/

carboplatin and pemetrexed/carboplatin. BMJ Case Rep. 2014. https:// doi. org/ 10. 1136/ bcr- 2014- 206225.

  97.  Winter G, Kirschner-Schwabe R, Groeneveld-Krentz S, Escherich G, Möricke A, von Stackelberg A, et al. Clinical and genetic characteristics 
of children with acute lymphoblastic leukemia and Li–Fraumeni syndrome. Leukemia. 2021. https:// doi. org/ 10. 1038/ s41375- 021- 01163-y.
  98.  Qian M, Cao X, Devidas M, Yang W, Cheng C, Dai Y, et al. TP53 germline variations influence the predisposition and prognosis of b-cell 

acute lymphoblastic leukemia in children. J Clin Oncol. 2018;36(6):591–9. https:// doi. org/ 10. 1200/ jco. 2017. 75. 5215.

  99.  Porter CC, Druley TE, Ayelet E, Kuiper RP, Kenan O, Schiffman JD, et al. Recommendations for surveillance for children with leukemia-

predisposing conditions. Clin Cancer Res. 2017. https:// doi. org/ 10. 1158/ 1078- 0432. ccr- 17- 0428.

 100.  Talwalkar SS, Cameron YC, Naeem RC, John HM, Strong LC, Abruzzo LV. Myelodysplastic syndromes arising in patients with germline 
TP53 mutation and Li-Fraumeni syndrome. Arch Pathol Lab Med. 2010;134(7):1010–5. https:// doi. org/ 10. 5858/ 2009- 0015- oa.1.
 101.  Kuykendall A, Duployez N, Boissel N, Lancet JE, Welch JS. Acute myeloid Leukemia: the good, the bad, and the ugly. Am Soc Clin Oncol 

Educ Book Am Soc Clin Oncol Annual Meet. 2018;38:555–73. https:// doi. org/ 10. 1200/ edbk_ 199519.

 102.  Mahesh S, Bannon Sarah A, Mark R, Kiran N, Kadia Tapan M, Koichi T, et al. Hematologic malignancies and Li–Fraumeni syndrome. Mol 

Case Stud. 2019;5(1):a003210.

 103.  Yamashita M, Dellorusso PV, Olson OC, Passegué E. Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis. Nat 

Rev Cancer. 2020;20(7):365–82. https:// doi. org/ 10. 1038/ s41568- 020- 0260-3.

 104.  Pepper C, Thomas A, Hoy T, Tighe J, Culligan D, Fegan C, et al. Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni 
syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs 
but not flavopiridol. Cell cycle (Georgetown, Tex). 2003;2(1):53–8.

 105.  George B, Kantarjian H, Baran N, Krocker JD, Rios A. TP53 in acute myeloid leukemia: molecular aspects and patterns of mutation. Int J 

Mol Sci. 2021;22(19):10782.

 106.  Regan H, Marren P. Melanoma and Li− Fraumeni syndrome: family history is not essential for screening recommendation. Clin Exp 

Dermatol. 2021;46(8):1567–8.

Vol:.(1234567890)Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w 

Review

 107.  Priscila G, Marnie R, Cristina C, Susana P, Josep M. Familial melanoma associated with Li-Fraumeni syndrome and atypical mole syndrome: 

total-body digital photography, dermoscopy and confocal microscopy. Acta Derm Venereol. 2017;97(6):720–3.

 108.  Sandru F, Dumitrascu MC, Petca A, Carsote M, Petca RC, Ghemigian A. Melanoma in patients with Li-Fraumeni syndrome (Review). Exp 

Ther Med. 2022;23(1):75. https:// doi. org/ 10. 3892/ etm. 2021. 10998.

 109.  Frebourg T, Bajalica LS, Oliveira C, Magenheim R, Evans DG, Hoogerbrugge N, et al. Guidelines for the Li–Fraumeni and heritable TP53-

related cancer syndromes. Euro J Human Genet. 2020;28(10):1379–86. https:// doi. org/ 10. 1038/ s41431- 020- 0638-4.

 110.  Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation 

carriers. J Clin Oncol. 2015;33(21):2345–52. https:// doi. org/ 10. 1200/ jco. 2014. 59. 5728.

 111.  Chompret A, Abel A, Stoppa-Lyonnet D, Brugiéres L, Pagés S, Feunteun J, et al. Sensitivity and predictive value of criteria for p53 germline 

mutation screening. J Med Genet. 2001;38(1):43–7. https:// doi. org/ 10. 1136/ jmg. 38.1. 43.

 112.  Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, et al. Prevalence and diversity of constitutional mutations in the p53 gene 

among 21 Li-Fraumeni families. Can Res. 1994;54(5):1298–304.

 113.  Eeles RA. Germline mutations in the TP53 gene. Cancer Surv. 1995;25:101–24.
 114.  Kumamoto T, Yamazaki F, Nakano Y, Tamura C, Tashiro S, Hattori H, et al. Medical guidelines for Li–Fraumeni syndrome 2019, version 1.1. 

Int J Clin Oncol. 2021;26(12):2161–78. https:// doi. org/ 10. 1007/ s10147- 021- 02011-w.

 115.  National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® version 3): Genetic/Familial 
High-Risk Assessment: Breast, Ovarian, and Pancreatic 2024 https:// www. nccn. org/ guide lines/ guide lines- detail? categ ory= 2& id= 1503. 
5 Sep 2024

 116.  Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H, et al. Biochemical and imaging surveillance in germline TP53 mutation 
carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol. 2016;17(9):1295–305. https:// 
doi. org/ 10. 1016/ S1470- 2045(16) 30249-2.

 117.  Kratz CP, Isabel AM, Laurence B, Thierry F, Garber JE, Greer MLC, et al. Cancer screening recommendations for individuals with Li-Fraumeni 

syndrome. Clin Cancer Res. 2017;23(11):e38–45. https:// doi. org/ 10. 1158/ 1078- 0432. ccr- 17- 0408.

 118.  Sánchez-Heras AB, Ramon y Cajal T, Pineda M, Aguirre E, Graña B, Chirivella I, et al. SEOM clinical guideline on heritable TP53-related 

cancer syndrome (2022). Clin Trans Oncol. 2023;25(9):2627–33. https:// doi. org/ 10. 1007/ s12094- 023- 03202-9.

 119.  Wong D, Luo P, Oldfield LE, Gong H, Brunga L, Rabinowicz R, et al. Early cancer detection in Li-Fraumeni syndrome with cell-free DNA. 

Cancer Discov. 2024;14(1):104–19. https:// doi. org/ 10. 1158/ 2159- 8290. cd- 23- 0456.

 120.  Mai Phuong L, Khincha Payal P, Loud Jennifer T, DeCastro RM, Bremer Renée C, Peters June A, et al. Prevalence of cancer at baseline 

screening in the National Cancer Institute Li-Fraumeni syndrome cohort. JAMA Oncol. 2017;3(12):1640–5.

 121.  Nees J, Kiermeier S, Struewe F, Keymling M, Maatouk I, Kratz CP, et al. Health behavior and cancer prevention among adults with li-

fraumeni syndrome and relatives in germany—a cohort description. Curr Oncol. 2022;29(10):7768–78.

 122.  Mai Phuong L, Best Ana F, Peters June A, DeCastro RM, Khincha Payal P, Loud Jennifer T, et al. Risks of first and subsequent cancers among 

TP53 mutation carriers in the national cancer institute Li-Fraumeni syndrome cohort. Cancer. 2016;122(23):3673–81.

 123.  Le Anh N, Harton J, Desai H, Powers J, Zelley K, Bradbury AR, et al. Frequency of radiation-induced malignancies post-adjuvant radio-

therapy for breast cancer in patients with Li-Fraumeni syndrome. Breast Cancer Res Treat. 2020;181:181–8.

 124.  Nathalie R, Christine F, Hans-Peter S, Nicola D, Christian S, Kerstin R, et al. Breast cancer characteristics and surgery among women with 

Li-Fraumeni syndrome in Germany—a retrospective cohort study. Cancer Med. 2021;10(21):7747–58.

 125.  Sabapathy K, Lane DP. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat Rev Clin 

Oncol. 2018. https:// doi. org/ 10. 1038/ nrcli nonc. 2017. 151.

 126.  Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. 

Curr Oncol. 2022;29(5):3044–60. https:// doi. org/ 10. 3390/ curro ncol2 90502 47.

 127.  Hoyos D, Zappasodi R, Schulze I, Sethna Z, de Andrade KC, Bajorin DF, et al. Fundamental immune–oncogenicity trade-offs define driver 

mutation fitness. Nature. 2022. https:// doi. org/ 10. 1038/ s41586- 022- 04696-z.

 128.  Crosby EJ, Wei J, Yang XY, Lei G, Wang T, Liu CX, et al. Complimentary mechanisms of dual checkpoint blockade expand unique T-cell 
repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. Oncoimmunology. 2018;7(5): e1421891. https:// 
doi. org/ 10. 1080/ 21624 02x. 2017. 14218 91.

 129.  Das A, Tabori U, Sambira Nahum LC, Collins NB, Deyell R, Dvir R, et al. Efficacy of nivolumab in pediatric cancers with high mutation 

burden and mismatch repair deficiency. Clin Cancer. 2023;29(23):4770–83. https:// doi. org/ 10. 1158/ 1078- 0432. ccr- 23- 0411.

 130.  Sokolova TN, Breder VV, Shumskaya IS, Suspitsin EN, Aleksakhina SN, Yanus GA, et al. Revisiting multiple erroneous genetic testing 
results and clinical misinterpretations in a patient with Li-Fraumeni syndrome: lessons for translational medicine. Hered Cancer Clin 
Pract. 2021;19(1):2. https:// doi. org/ 10. 1186/ s13053- 020- 00157-8.

 131.  Lu Y, Wu M, Xu Y, Yu L. The development of p53-targeted therapies for human cancers. Cancers. 2023. https:// doi. org/ 10. 3390/ cance  

rs151 43560.

 132.  Carlsen L, Zhang S, Tian X, De La Cruz A, George A, Arnoff TE, et al. The role of p53 in anti-tumor immunity and response to immuno-

therapy. Front Mol Biosci. 2023. https:// doi. org/ 10. 3389/ fmolb. 2023. 11483 89.

 133.  Dumbrava Ecaterina E, Mahipal A, Gao X, Shapiro G, Starr JS, Singh P, et al. Phase 1/2 study of eprenetapopt (APR-246) in combination 
with pembrolizumab in patients with solid tumor malignancies. J Clin Oncol. 2021. https:// doi. org/ 10. 1200/ JCO. 2021. 39. 15_ suppl. TPS31 
61.

 134.  Hoy SM. Sintilimab: first global approval. Drugs. 2019;79(3):341–6. https:// doi. org/ 10. 1007/ s40265- 019- 1066-z.
 135.  Wang J, Shang Z, Wang J, Xu J, Li W, Guan Y, et al. MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma 

receiving CAR T cell immunotherapy. J Immunothera Cancer. 2021. https:// doi. org/ 10. 1136/ jitc- 2020- 002029.

 136.  Colgan JN, Fuentes-Bolanos NA, Barbaric D, Dalla-Pozza L, Mitchell R, Samarasinghe S, et al. Scylla and Charybdis: unpalatable choices 
in managing hypodiploid acute lymphoblastic leukemia. EJC Paediat Oncol. 2023. https:// doi. org/ 10. 1016/j. ejcped. 2023. 100133.
 137.  Jacover A, Zarbiv Y, Tal KH, Klein S, Breuer S, Durst R, et al. Tumor-infiltrating lymphocyte transfusion in a patient with treatment refrac-

tory triple negative breast cancer. Cancer Rep. 2023. https:// doi. org/ 10. 1002/ cnr2. 1894.

Vol.:(0123456789)Review 

Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w

 138.  Deniger DC, Pasetto A, Robbins PF, Gartner JJ, Prickett TD, Paria BC, et al. T-cell responses to TP53 “hotspot” mutations and unique 
neoantigens expressed by human ovarian cancers. Clin Cancer Res. 2018;24(22):5562–73. https:// doi. org/ 10. 1158/ 1078- 0432.  
ccr- 18- 0573.

 139.  Chen L, Xu B, Long X, Gu J, Lou Y, Wang D, et al. CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient 

in the context of Li-Fraumeni syndrome. J Immunothera Cancer. 2020. https:// doi. org/ 10. 1136/ jitc- 2019- 000364.

 140.  Jia W, Min X, Zekai M, Na W, Yang C, Yi X, et al. Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell 
cocktail alone or in combination with ASCT. Signal Transduct Target Ther. 2022;7(1):101. https:// doi. org/ 10. 1038/ s41392- 022- 00924-0.
 141.  Tianyi Z, Jing H, Liu Y, Zhengdong C, Wei S, Yingqi H, et al. Immune microenvironment in osteosarcoma: components, therapeutic strate-

gies and clinical applications. Front Immunol. 2022. https:// doi. org/ 10. 3389/ fimmu. 2022. 907550.

 142.  Sim Geok C, Radvanyi L. The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev. 2014;25(4):377–90.
 143.  Jebain J, Siller A Jr, Gill P, Prieto VG, Tyring SK. Recurrence of mucosal melanoma in Li-Fraumeni syndrome: A follow-up of an index case. 

JAAD Case Rep. 2021;10:31–3.

 144.  Qunfang L, Tang L, Roberts Paul C, Kraniak JM, Fridman AL, Kulaeva Olga I, et al. Interferon regulatory factors IRF5 and IRF7 inhibit growth 

and induce senescence in immortal Li-Fraumeni fibroblasts. Mol Cancer Res. 2008;6(5):770–84.

 145.  Shalom M, Einav H, Ido G, Yan S, Ira K-S, Iris K, et al. Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon 

beta. PLoS ONE. 2013;8(4): e61353.

 146.  Zawacka JE. p53 biology and reactivation for improved therapy in MDS and AML. Biomarker Res. 2024;12(1):34. https:// doi. org/ 10. 1186/ 

s40364- 024- 00579-9.

 147.  Tuval A, Strandgren C, Heldin A, Palomar-Siles M, Wiman KG. Pharmacological reactivation of p53 in the era of precision anticancer 

medicine. Nat Rev Clin Oncol. 2024. https:// doi. org/ 10. 1038/ s41571- 023- 00842-2.

 148.  Park H, Shapiro GI, Gao X, Mahipal A, Starr J, Furqan M, et al. Phase Ib study of eprenetapopt (APR-246) in combination with pembroli-
zumab in patients with advanced or metastatic solid tumors. ESMO Open. 2022. https:// doi. org/ 10. 1016/j. esmoop. 2022. 100573.
 149.  Peng X, Zhang MQ, Conserva F, Hosny G, Selivanova G, Bykov VJ, et al. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and con-

verts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013;4(10): e881. https:// doi. org/ 10. 1038/ cddis. 2013. 417.

 150.  Ou A, Zhao X, Lu Z. The potential roles of p53 signaling reactivation in pancreatic cancer therapy. Biochimica et Biophysica Acta (BBA) 

- Rev on Cancer. 2022. https:// doi. org/ 10. 1016/j. bbcan. 2021. 188662.

 151.  Abel Melissa L, Takahashi N, Peer C, Redon CE, Nichols S, Vilimas R, et al. Targeting replication stress and chemotherapy resistance with 

a combination of sacituzumab govitecan and berzosertib: a phase I clinical trial. Clin Cancer Res. 2023;29(18):3603–11.

 152.  Parkes  A,  Arun  BK,  Litton  JK.  Systemic  treatment  strategies  for  patients  with  hereditary  breast  cancer  syndromes.  Oncologist. 

2017;22(6):655–66. https:// doi. org/ 10. 1634/ theon colog ist. 2016- 0430.

 153.  Smith HL, Harriet S, Tweddle DA, Curtin NJ. DNA damage checkpoint kinases in cancer. Expert Rev Mol Med. 2020. https:// doi. org/ 10. 

1017/ erm. 2020.3.

 154.  Akiyoshi K, Takeshi O, Shohei U, Chinatsu M, Takafumi M, Takaaki F, et al. Molecular features and clinical management of hereditary 

pancreatic cancer syndromes and familial pancreatic cancer. Int J Mol Sci. 2022;23(3):1205.

 155.  Reed DE, Shokat KM. Targeting osteosarcoma. Proc Natl Acad Sci. 2014;111(51):18100–1. https:// doi. org/ 10. 1073/ pnas. 14205 96111.
 156.  Aitken MJL, Lee HJ, Post SM. Emerging treatment options for patients with p53-pathway-deficient CLL. Therapeutic Adv Hematol. 

2019;10:2040620719891356. https:// doi. org/ 10. 1177/ 20406 20719 891356.

 157.  Palma M, Mulder TA, Österborg A. BTK inhibitors in chronic lymphocytic leukemia: biological activity and immune effects. Front Immunol. 

2021. https:// doi. org/ 10. 3389/ fimmu. 2021. 686768.

 158.  Nakhoda S, Vistarop A, Wang YL. Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin 

lymphoma. Br J Haematol. 2023;200(2):137–49. https:// doi. org/ 10. 1111/ bjh. 18418.

 159.  Liren J, Joanna Z-P. The p53/MDM2/MDMX-targeted therapies—a clinical synopsis. Cell Death Dis. 2020;11(4):237. https:// doi. org/ 10. 

1038/ s41419- 020- 2445-9.

 160.  Gounder MM, Bauer TM, Schwartz GK, Weise AM, Patricia L, Prasanna K, et al. A first-in-human phase i study of milademetan, an MDM2 
Inhibitor, in patients with advanced liposarcoma, solid tumors, or lymphomas. J Clin Oncol. 2023. https:// doi. org/ 10. 1200/ jco. 22. 01285.
 161.  Haolan W, Ming G, Hudie W, Yongheng C. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct 

Target Ther. 2023;8(1):92. https:// doi. org/ 10. 1038/ s41392- 023- 01347-1.

 162.  LoRusso P, Yamamoto N, Patel MR, Laurie SA, Bauer TM, Geng J, et al. The MDM2-p53 Antagonist Brigimadlin (BI 907828) in patients 
with advanced or metastatic solid tumors: results of a phase Ia, first-in-human. Dose-Escalation Study Cancer Dis. 2023;13(8):1802–13. 
https:// doi. org/ 10. 1158/ 2159- 8290. cd- 23- 0153.

 163.  Guerlavais V, Sawyer TK, Carvajal L, Chang YS, Graves B, Jian-Guo R, et al. Discovery of sulanemadlin (ALRN-6924), the first cell-permeating, 

stabilized α-helical peptide in clinical development. J Med Chem. 2023. https:// doi. org/ 10. 1021/ acs. jmedc hem. 3c006 23.

 164.  Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, et al. Mutational profile and prognostic significance of TP53 in diffuse large 
B-cell lymphoma patients treated with R-CHOP: report from an international DLBCL Rituximab-CHOP consortium program study. Blood. 
2012;120(19):3986–96. https:// doi. org/ 10. 1182/ blood- 2012- 05- 433334.

 165.  Zhong W, Xu X, Zhu Z, Yang L, Du H, Xia Z, et al. Increased interleukin-17A levels promote rituximab resistance by suppressing p53 expres-
sion and predict an unfavorable prognosis in patients with diffuse large B cell lymphoma. Int J Oncol. 2018;52(5):1528–38. https:// doi. 
org/ 10. 3892/ ijo. 2018. 4299.

 166.  Stefaniuk P, Onyszczuk J, Szymczyk A, Podhorecka M. Therapeutic options for patients with tp53 deficient chronic lymphocytic leukemia: 

narrative review. Cancer Manag Res. 2021;13:1459–76. https:// doi. org/ 10. 2147/ cmar. s2839 03.

 167.  Chi SG, Minami Y. Emerging targeted therapy for specific genomic abnormalities in acute myeloid leukemia. Int J Mol Sci. 2022. https:// 

doi. org/ 10. 3390/ ijms2 30423 62.

 168.  Tarhini AA, Kirkwood JM, Tawbi H, Gooding WE, Islam MF, Agarwala SS. Safety and efficacy of arsenic trioxide for patients with advanced 

metastatic melanoma. Cancer. 2008;112(5):1131–8. https:// doi. org/ 10. 1002/ cncr. 23284.

 169.  Jiabing Li, Shujun X, Fangfang S, Song Huaxin Wu, Jiaqi ZD, et al. Arsenic trioxide extends survival of Li–Fraumeni syndrome mimicking 

mouse. Cell Death Dis. 2023;14(11):783. https:// doi. org/ 10. 1038/ s41419- 023- 06281-2.

Vol:.(1234567890)Discover Oncology          (2024) 15:561  

| https://doi.org/10.1007/s12672-024-01435-w 

Review

 170.  Jiang Y, Shen X, Zhi F, Wen Z, Gao Y, Xu J, et al. An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: 

basic concepts and clinical implications. Cell Death Disc. 2023;9(1):266. https:// doi. org/ 10. 1038/ s41420- 023- 01558-z.

 171.  Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol. 

2003;21(19):3609–15. https:// doi. org/ 10. 1200/ jco. 2003. 10. 009.

 172.  Zoe L, Michael A, Ellie VV, Wenlong L, Ashlyn C, Winpa A, et al. Arsenic-induced neurotoxicity in patients with acute promyelocytic leu-

kaemia. Brit J Haematol. 2024. https:// doi. org/ 10. 1111/ bjh. 19297.

 173.  Naseri A, Sanaie S, Hamzehzadeh S, Seyedi-Sahebari S, Hosseini MS, Gholipour-Khalili E, et al. Metformin: new applications for an old 

drug. J Basic Clin Physiol Pharmacol. 2023;34(2):151–60. https:// doi. org/ 10. 1515/ jbcpp- 2022- 0252.

 174.  Mahmoudi G, Ehteshaminia Y, Kokhaei P, Jalali Seyedeh F, Jadidi-Niaragh F, Pagheh Abdol S, et al. Enhancement of targeted therapy in 
combination with metformin on human breast cancer cell lines. Cell Commun Signal. 2024. https:// doi. org/ 10. 1186/ s12964- 023- 01446-0.
 175.  Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–85. https:// doi. org/ 10. 1007/ 

s00125- 017- 4342-z.

 176.  Garcia D, Shaw RJ. AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance. Mol Cell. 2017. https:// doi. org/ 

10. 1016/j. molcel. 2017. 05. 032.

 177.  Drzewoski J, Hanefeld M. The current and potential therapeutic use of metformin-the good old drug. Pharmaceuticals. 2021. https:// 

doi. org/ 10. 3390/ ph140 20122.

 178.  Shu-Man HL, Shu-Ting L, Yung-Lung C, Ching-Liang H, Shih-Ming H. Metformin causes cancer cell death through downregulation of 

p53-dependent differentiated embryo chondrocyte 1. J Biomed Sci. 2018. https:// doi. org/ 10. 1186/ s12929- 018- 0478-5.

 179.  Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD(+) metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 

2021;22(2):119–41. https:// doi. org/ 10. 1038/ s41580- 020- 00313-x.

 180.  Pang N, Hu Q, Zhou Y, Xiao Y, Li W, Ding Y, et al. Nicotinamide adenine dinucleotide precursor suppresses hepatocellular cancer progres-

sion in mice. Nutrients. 2023. https:// doi. org/ 10. 3390/ nu150 61447.

 181.  Katayoshi T, Nakajo T, Tsuji-Naito K. Restoring NAD+ by NAMPT is essential for the SIRT1/p53-mediated survival of UVA- and UVB-irradiated 

epidermal keratinocytes. J Photochem Photobiol B Biol. 2021. https:// doi. org/ 10. 1016/j. jphot obiol. 2021. 112238.

 182.  Navas LE, Amancio C. NAD+ metabolism, stemness, the immune response, and cancer. Signal Transd and Targeted Therapy. 2021. https:// 

doi. org/ 10. 1038/ s41392- 020- 00354-w.

 183.  Valentina A, Tiziana V, Sara S, Davide R, Daniela G, Giovanni DA, et al. Nicotinamide promotes apoptosis in chronic lymphocytic leukemia 
through activation of the p53/Mir-34a/SIRT1 tumor suppressor network. Blood. 2010. https:// doi. org/ 10. 1182/ blood. V116. 21. 4627. 4627.
 184.  McBride Kate A, Ballinger Mandy L, Killick E, Kirk J, Tattersall Martin HN, Eeles Rosalind A, et al. Li-Fraumeni syndrome: cancer risk assess-

ment and clinical management. Nat Rev Clin Oncol. 2014. https:// doi. org/ 10. 1038/ nrcli nonc. 2014. 41.

 185.  Kwong A, Ho CYS, Shin VY, Au CH, Chan TL, Ma ESK. How does re-classification of variants of unknown significance (VUS) impact 
the management of patients at risk for hereditary breast cancer? BMC Med Genomics. 2022;15(1):122. https:// doi. org/ 10. 1186/  
s12920- 022- 01270-4.

 186.  Tam B, Sinha S, Qin Z, Wang SM. Comprehensive identification of deleterious TP53 missense VUS variants based on their impact on TP53 

structural stability. Int J Mol Sci. 2021. https:// doi. org/ 10. 3390/ ijms2 22111 345.

 187.  Fortuno C, Lee K, Olivier M, Pesaran T, Mai PL, de Andrade KC, et al. Specifications of the ACMG/AMP variant interpretation guidelines 

for germline TP53 variants. Hum Mutat. 2021;42(3):223–36. https:// doi. org/ 10. 1002/ humu. 24152.

 188.  Clinical Domain Working Groups. TP53 Variant Curation Expert Panel. https:// clini calge nome. org/ affil iation/ 50013/. Accessed 5 Sep 2024
 189.  Coombs CC, Gillis NK, Tan X, Berg JS, Ball M, Balasis ME, et al. Identification of clonal hematopoiesis mutations in solid tumor patients 
undergoing unpaired next-generation sequencing assays. Clin Cancer Res. 2018;24(23):5918–24. https:// doi. org/ 10. 1158/ 1078- 0432. 
ccr- 18- 1201.

 190.  Coffee B, Cox HC, Bernhisel R, Manley S, Bowles K, Roa BB, et al. A substantial proportion of apparently heterozygous TP53 pathogenic vari-
ants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically. Hum Mutat. 2020;41(1):203–11. 
https:// doi. org/ 10. 1002/ humu. 23910.

 191.  Sokolova A, Johnstone KJ, McCart Reed AE, Simpson PT, Lakhani SR. Hereditary breast cancer: syndromes, tumour pathology and 

molecular testing. Histopathology. 2023;82(1):70–82. https:// doi. org/ 10. 1111/ his. 14808.

 192.  Ruijs Marielle WG, Broeks A, Menko Fred H, Ausems Margreet GEM, Wagner A, Oldenburg R, et al. The contribution of CHEK2 to the TP53-

negative Li-Fraumeni phenotype. Hered Cancer Clin Pract. 2009. https:// doi. org/ 10. 1186/ 1897- 4287-7-4.

 193.  Apostolou P, Papasotiriou I. Current perspectives on CHEK2 mutations in breast cancer. Breast Cancer. 2017;9:331–5. https:// doi. org/ 10. 

2147/ bctt. s1113 94.

 194.  Ranju R, Jatinder K, Rolf K, Lisa W. Links between DNA double strand break repair and breast cancer: accumulating evidence from both 

familial and nonfamilial cases. Cancer Lett. 2007. https:// doi. org/ 10. 1016/j. canlet. 2006. 06. 004.

 195.  Fortuno C, Richardson M, Pesaran T, Yussuf A, Horton C, James PA, et al. CHEK2 is not a Li-Fraumeni syndrome gene: time to update public 

resources. J Med Genet. 2023;60(12):1215–7. https:// doi. org/ 10. 1136/ jmg- 2023- 109464.

 196.  Underkofler KA, Thomas MH, Taylor CJ, Mazur CL, Erickson SH, Ring KL. Factors affecting adherence to a high-risk surveillance protocol 
among patients with Li-Fraumeni syndrome. Hered Cancer Clin Pract. 2023;21(1):15. https:// doi. org/ 10. 1186/ s13053- 023- 00259-z.
 197.  Tak CR, Biltaji E, Kohlmann W, Maese L, Hainaut P, Villani A, et al. Cost-effectiveness of early cancer surveillance for patients with Li-

Fraumeni syndrome. Pediatr Blood Cancer. 2019;66(5): e27629. https:// doi. org/ 10. 1002/ pbc. 27629.

 198.  Vaez-Gharamaleki Y, Hosseni MS. Improved access to the innovative anticancer therapies in resource-limited countries: call for global 

action. Int J Surg. 2024;110(7): 4477–8. https:// doi. org/ 10. 1097/ JS9. 00000 00000 001413

 199.  Joshi P, Bhandari S, Tk A, Kaur S, Bhargava R, Tansir G, et al. A qualitative study to assess the psychological experiences and coping strate-
gies of families affected with Li-Fraumeni syndrome in the Indian population. Rare tumors. 2023;15:20363613231186300. https:// doi. 
org/ 10. 1177/ 20363 61323 11863 00.

Publisher’s Note  Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Vol.:(0123456789)